Home 

Private access

  • Division BASIC

    Head of division : Nicolas MANEL

    To come

    Head of division : Olivier SCHWARTZ

    Olivier SCHWARTZPr Olivier Schwartz is heading the Virus & Immunity Unit at Institut Pasteur since 2007.

    He is the former president of the Scientific Council of Institut Pasteur (2009-2011) and fo rmer director of the Virology Department (2012-2014).

    He is studying HIV and Chikungunya replication, and the host innate and adaptive immune responses induced by these viruses. Olivier Schwartz is one of the leaders of the Basic division of the VRI


    Selected publicactions

    [1] Lahouassa H, Blondot ML, Chauveau L, Chougui G, Morel M, Leduc M, Guillonneau F, Ramirez BC, Schwartz O, Margottin-Goguet F. HIV-1 Vpr degrades the HLTF DNA translocase in T cells and macrophages. PNAS. 2016; 113(19):5311-6.
    [2] Donahue DA, Amraoui S, di Nunzio F, Kieffer C, Porrot F, Opp S, Diaz-Griffero F, Casartelli N, Schwartz O. SUN2 overexpression deforms nuclear shape and inhibits HIV. Journal of Virology 2016; 90(8):4199-214.
    [3] Bruel T, Guivel-Benhassine F, Amraoui S, Malbec M, Richard L, Bourdic K, Donahue DA, Lorin V, Casartelli N, Noël N, Lambotte O, Mouquet H, Schwartz O. Elimination of HIV-1 infected cells by broadly neutralizing antibodies. Nature Communications, 2016; 7:10844.
    [4] Ayinde D, Bruel T, Cardinaud S, Porrot F, Prado J, Moris A, Schwartz O. SAMHD1 limits HIV-1 recognition and killing of infected dendritic cells by cytotoxic T lymphocytes. Journal of Virology 2015; 89(14):6994-7006.
    [5] Ruffin N, Brezar V, Ayinde D, Lefebvre C, Schulze Zur Wiesch J, van Lunzen J, Bockhorn M, Schwartz O, Hocini H, Lelievre JD, Banchereau J, Levy Y, Seddiki N. Resident and circulating effector/memory CD4+ T-cells lacking SAMHD1 are highly sensitive to HIV-1 infection. AIDS 2015; 13; 29(5):519-30.
    [6] Chauveau L, Puigdomenech I, Ayinde D, Roesch F, Porrot F, Bruni D, Visseaux B, Descamps D, Schwartz O. HIV-2 infects resting CD4+ T cells but not monocyte-derived dendritic cells. Retrovirology 2015; 12:2.
    [7] Quillay H, El Costa H, Marlin R, Duriez M, Cannou C, Chretien F, Fernandez H, Lebreton A, Ighil J, Schwartz O, Barre-Sinoussi F, Nugeyre MT, Menu E. Distinct Characteristics of Endometrial and Decidual Macrophages and Regulation of Their Permissivity to HIV-1 Infection by SAMHD1. Journal of Virology 2015; 89:1329-1339.
    [8] Compton A, Bruel T, Porrot F, Mallet A, Sachse M, Euvrard M, Liang C, Casartelli N, and Schwartz O. Interferon-induced transmembrane proteins incorporate into HIV-1 virions and impair viral cell-to-cell spread. Cell Host & Microbe 2014; 16(6):736-47.
    [9] Malbec M, Mouquet H, Schwartz O. Les anticorps anti-VIH-1 et la transmission virale de cellule à cellule. Medecine/Sciences (Paris) 2014; 30:508-510.
    [10] Malbec M, Porrot F, Rua R, Horwitz J, Klein F, Halper-Stromberg A, Scheid J, Eden C, Mouquet H, Nussenzweig MC, Schwartz O. Broadly neutralizing antibodies that inhibit HIV-1 cell-to-cell transmission. Journal of Experimental Medicine 2013; 210(13):2813-21.

    Monsef BENKIRANE

    To come

    Philippe BOUSSO

    Philippe BOUSSOPhilippe Bousso is an immunologist heading the Dynamics of Immune Responses Unit at the Pasteur Institute. With the help of innovative functional imaging approaches, his research aims at understanding and manipulating immune responses in the context of disease pathogenesis.

    Over the last years, his lab helped redefine the process of T cell activation in vivo. His work in the field of infectious diseases offered the first demonstration that effector cytokines were acting over extended distances in the infected tissue to effectively control intracellular pathogens. His lab also characterized a novel cellular pathway responsible for graft rejection.

    In the context of tumor immunity, his group identified the distinct roles of T cells and NK cells in tumor cell killing and uncovered the mode of action of anti-CD20 therapy, the most common immunotherapy used to treat B cell lymphomas. Finally, his lab has recently characterized the mode of action of the anti-HIV candidate vaccine MVA.

    Philippe Bousso is PI in the Basic division of the VRI.


    Selected publications

    [1] Sagoo P, Garcia Z, Breart B, Lemaître F, Michonneau D, Albert ML, Levy Y, Bousso P. In vivo imaging of inflammasome activation reveals a subcapsular macrophage burst response that mobilizes innate and adaptive immunity. Nature Medicine 2016; 22:64-71.
    [2] Michonneau D, Sagoo P, Breart B, Garcia Z, Celli S, Bousso P. The PD-1 axis enforces an anatomical segregation of CTL activity that creates tumor niches after allogeneic hematopoietic stem cell transplantation. Immunity 2016; 44:143-154.
    [3] Olekhnovitch R, Ryffel B, Müller AJ, Bousso P. Collective nitric oxide production provides tissue-wide immunity during Leishmania infection. Journal of Clinical Investigation 2014; 124(4):1711-22.
    [4] Montalvao F, Garcia Z, Celli S, Breart B, Deguine J, Van Rooijen N, Bousso P. The mechanism of anti-CD20-mediated B cell depletion revealed by intravital imaging. Journal of Clinical Investigation 2013; 123(12):5098-103.
    [5] Müller AJ, Aeschlimann S, Olekhnovitch R, Dacher M, Späth GF, Bousso P. Photoconvertible pathogen labeling reveals nitric oxide control of Leishmania major infection in vivo via dampening of parasite metabolism. Cell Host Microbe 2013; 14(4):460-7
    [6] Garrod KR, Moreau HD, Garcia Z, Lemaître F, Bouvier I, Albert ML, Bousso P. Dissecting T cell contraction in vivo using a genetically encoded reporter of apoptosis. Cell Reports 2012; 2(5):1438-47
    [7] Müller AJ, Filipe-Santos O, Eberl G, Aebischer T, Späth GF, Bousso P. CD4+ T cells rely on a cytokine gradient to control intracellular pathogens beyond sites of antigen presentation. Immunity 2012; 37(1):147-57
    [8] Moreau HD, Lemaître F, Terriac E, Azar G, Piel M, Lennon-Dumenil AM, Bousso P. Dynamic in situ cytometry uncovers T cell receptor signaling during immunological synapses and kinapses in vivo. Immunity 2012; 37(2):351-63
    [9] Garcia Z, Lemaître F, van Rooijen N, Albert ML, Levy Y, Schwartz O, Bousso P. Subcapsular sinus macrophages promote NK cell accumulation and activation in response to lymph-borne viral particles. Blood 2012; 120(24):4744-50.
    [10] Celli S, Albert ML, Bousso P. Visualizing the innate and adaptive immune responses underlying allograft rejection by two-photon microscopy. Nature Medicine 2011; 17(6):744-9.

    James DI SANTO

    James Di SANTOJames Di Santo received a combined M.D./Ph.D. in 1989/1991 from Cornell University Medical College and the Memorial Sloan–Kettering Cancer Center, and completed post-doctoral training with Alain Fischer in Paris, where he characterized several genes responsible for primary human immunodeficiency syndromes.

    In 1994, he joined the Institut National de la Santé et de la Recherche Médicale (Inserm) as a permanent staff scientist. In 1999, he moved his laboratory to the Immunology Department of the Institut Pasteur, where he directed the Immunology Department from 2002-2006. HIs research interests include defining the role of cytokines in lymphoid development, and understanding the differentiation of natural killer cells and other innate lymphoid cells.

    In the context of the VRI, he will investigate combination immunotherapies to eliminate HIV-1 reservoirs using novel ‘humanized’ mouse models.

    James Di Santo is PI in the Basic division of the VRI.


    Selected publications

    [1] Li Y, Mention JJ, Court N, Masse-Ranson G, Toubert A, Spits H, Legrand N, Corcuff E, Strick-Marchand H and Di Santo JP. A novel Flt3-deficient HIS mouse model with selective enhancement of human DC development. European Journal of Immunology 2016; 46:1291-1299.
    [2] Strick-Marchand H, Dusséaux M, Darche S, Huntington ND, Legrand N, Masse-Ranson G, Corcuff E, Ahodantin J, Weijer K, Spits H, Kremsdorf D, and Di Santo JP. A novel mouse model for stable engraftment of a human immune system and human hepatocytes. PLoS One 2015; 10:e0119820.
    [3] Yusa K, Rashid ST, Strick-Marchand H, Miranda E, Ordonez A, Hannan N, Rohani F, Alexander G, Marciniak SJ, Gregory PD, Di Santo JP, Lomas DA, Bradley A and Vallier L. Efficient bi-allelic correction of a1-antitrypsin deficiency in human induced pluripotent stem cells. Nature 2011; 478:391-394.
    [4] Huntington ND, Alves NL, Legrand N, Lim A, Strick-Marchand H, Mention JJ, Plet A, Weijer K, Jacques Y, Becker PD, Guzman C, Soussan P, Kremsdorf D, Spits H, and Di Santo JP. IL-15 transpresentation promotes both human T-cell reconstitution and T-cell-dependent antibody responses in vivo. PNAS 2011; 108:6217-6222.
    [5] Huntington ND, Alves NL, Legrand N, Lim A, Strick-Marchand H, Plet A, Weijer K, Jacques Y, Spits H, and Di Santo JP. Autonomous and extrinsic regulation of thymopoiesis in human immune system (HIS) mice. European Journal of Immunology 2011; 41:2883-2893.
    [6] Huntington ND, Legrand N, Alves NL, Jaron B, Weijer K, Plet A, Corcuff E, Mortier E, Jacques Y, Spits H and Di Santo JP. IL-15 trans-presentation promotes human NK cell development and terminal differentiation in vivo. Journal of Experimental Medicine 2009; 206:25-34.

    Nabila SEDDIKI

    Nabila SEDDIKINabila Seddiki is a Senior Lecturer at the Paris-Est Créteil University (UPEC). She holds an INSERM “Chaire d’Excellence en Immunologie et Maladies Infectieuses”. She joined the VRI end of 2010. Before that she was a Research Fellow at the Centenary Institute (University of Sydney) and then a Senior Scientist at the National Centre for HIV Epidemiology and Clinical Research (University of New South Wales).

    Dr Seddiki’s research interests focus on the cellular and molecular characterization of T-cell subsets. She is particularly interested in investigating the dynamics of antigen-specific T regulatory, T follicular helper and effector CD4+ T-cell subsets in viral infections. More recently, she has been investigating the role of microRNA and chromatin remodeling in the regulation of target molecules during HIV-1 infection.

    Nabila Seddiki is PI in the Basic division of the VRI.


    Selected publications

    [1] Brezar V., Tu WJ and N. Seddiki. PKC-t in regulatory and Effector T-cell functions. Frontiers in Immunology 2015; 6:530.
    [2] Brezar V, N. Ruffin, L. Richert, M. Surenaud, C. Lacabaratz, K. Palucka, R. Thiébaut, J. Banchereau, Y. Levy and N. Seddiki. Decreased HIV-specific T-regulatory responses are associated with effective DC-vaccine induced immunity. PLoS Pathogens 2015; 11(3):e1004752.
    [3] Ruffin N, V Brezar, D Ayinde, C Lefebvre, J Schulze Zur Wiesch, J van Lunzen, M Bockhorn, O Schwartz, H Hocini, JD Lelievre, J Banchereau, Y Levy and N Seddiki. Low SAMHD1 expression following T-cell activation and proliferation renders CD4+ T cells susceptible to HIV-1. AIDS 2015; 29:519-30.
    [4] Seddiki N, Cook L, Hsu DC, Phetsouphanh C et al. Human antigen-specific CD4+CD25+CD134+CD39+ T cells are enriched for regulatory T cells and comprise a substantial proportion of recall responses. European Journal of Immunology 2014; 44(6):1644-61.
    [5] Brezar V, Ruffin N, Lévy Y, Seddiki N. A highly relevant and efficient single step method for simultaneous depletion and isolation of human regulatory T cells in a clinical setting. Journal of Immunology Methods 2014; 411:70-5.
    [6] Jenabian MA, Seddiki N, Yatim A, Carriere M, Hulin A et al. Regulatory T Cells Negatively Affect IL-2 Production of Effector T Cells through CD39/Adenosine Pathway in HIV Infection. Plos Pathogens 2013; 9(4):e1003319.
    [7] Seddiki N, Swaminathan S, Phetsouphanh C and AK Kelleher. miR-155 is differentially expressed in Treg subsets, which may explain expression level differences of miR-155 in HIV-1 infected patients. Blood, 2012; 119(26):6396-7.
    [8] Sutcliffe EL, Bunting KL, He YQ, Li J, Phetsouphanh C, Seddiki N, Zafar A et al. Chromatin-associated protein kinase C-θ regulates an inducible gene expression program and microRNAs in human T lymphocytes. Molecular Cell, 2011; 41(6):704-19.
    [9] Seddiki N, Santner-Nanan B., Martinson J., Zaunders J, Sasson S., Landay A., Nanan R., Kelleher AD and B. Fazekas de St Groth. Expression of IL-2 and L-7 receptors discriminates between human regulatory and activated T cells. Journal of Experimental Medicine 2006; 203:1693.
    [10] Seddiki N, B. Santner-Nanan, et al. Characterization of human CD4+CD25+ T cells in lymph nodes, cord and adult blood. Blood 2006; 107:2830-2838.

  • Division DC-BASED VACCINES

    Head of division : Gerard ZURAWSKI

    Gerard ZURAWSKII have been an Investigator at the Baylor Institute for Immunology Research (BIIR) since 2004 and am currently a BIIR Co-Director and Director for the BIIR Center for Biotechnology.

    I trained as a bacterial geneticist and received my Ph.D. from the Sydney University in Australia and trained in Molecular Biology at Stanford University, California and the C.S.I.R.O., Canberra.

    I am an expert in Molecular Biology and Protein Engineering, specializing in the immune system. Most particularly, in 21 years of work at the DNAX Research Institute, I identified and characterized cytokines and their receptor interactions, including IL-13, and IL-25. I directed the DNAX Genomics Division that was immensely successful in mining expressed sequence tag data for cytokine and cytokine receptor discovery and subsequent biological characterizations.

    At BIIR, I have led a vaccine-development program based on targeting antigens directly to human dendritic cells using antibody-antigen conjugates. Currently, with this platform technology our BIIR team and outside collaborators have successfully tested in human in vitro systems, as well as in mouse and monkey in vivo studies, novel vaccines against influenza, cancers, HIV, HCV, and HPV.

    Vaccines based on these studies are now in clinical development for HIV-1 therapeutic and prophylactic applications and for treatment on HPV-based cancers of the mucosa.
    Gerard Zurawski is the leader of the DC-based vaccines division of the VRI


    Selected publicactions

    [1] Zurawski G, Zurawski S, Flamar AL, Richert L, Wagner R, Tomaras GD, et al. Targeting HIV-1 Env gp140 to LOX-1 Elicits Immune Responses in Rhesus Macaques. PloS One 2016; 11(4):e0153484.
    [2] Flamar AL, Contreras V, Zurawski S, Montes M, Dereuddre-Bosquet N, Martinon F, Banchereau J, Le Grand R, Zurawski G, Levy Y. Delivering HIV Gagp24 to DCIR Induces Strong Antibody Responses In Vivo. PLoS One 2015;10(9):e0135513.
    [3] Joo H, Upchurch K, Zhang W, Ni L, Li D, Xue Y, Li XH, Hori T, Zurawski S, Liu YJ, Zurawski G, Oh S. Opposing Roles of Dectin-1 Expressed on Human Plasmacytoid Dendritic Cells and Myeloid Dendritic Cells in Th2 Polarization. Jounal of Immunology 2015; 195(4):1723-31.
    [4] Levy Y, Thiebaut R, Montes M, Lacabaratz C, Sloan L, King B, et al. Dendritic cell-based therapeutic vaccine elicits polyfunctional HIV-specific T-cell immunity associated with control of viral load. European Journal of Immunology. 2014; 44(9):2802-10.
    [5] Skinner JA, Zurawski SM, Sugimoto C, Vinet-Oliphant H, Vinod P, Xue Y, Russell-Lodrigue K, Albrecht RA, García-Sastre A, Salazar AM, Roy CJ, Kuroda MJ, Oh S, Zurawski G. Immunologic characterization of a rhesus macaque H1N1 challenge model for candidate influenza virus vaccine assessment. Clinical Vaccine Immunology 2014; 21(12):1668-80.
    [6] Epaulard O, Adam L, Poux C, Zurawski G, Salabert N, Rosenbaum P, Dereuddre-Bosquet N, Zurawski S, Flamar AL, Oh S, Romain G, Chapon C, Banchereau J, Lévy Y, Le Grand R, Martinon F. Macrophage- and neutrophil-derived TNF-α instructs skin langerhans cells to prime antiviral immune responses. Journal of Immunology 2014; 193(5):2416-26.
    [7] Joo H, Li D, Dullaers M, Kim TW, Duluc D, Upchurch K, Xue Y, Zurawski S, Le Grand R, Liu YJ, Kuroda M, Zurawski G, Oh S. C-type lectin-like receptor LOX-1 promotes dendritic cell-mediated class-switched B cell responses. Immunity 2014; 41(4):592-604.
    [8] Flamar AL, Xue Y, Zurawski SM, Montes M, King B, Sloan L, Oh S, Banchereau J, Levy Y, Zurawski G. Targeting concatenated HIV antigens to human CD40 expands a broad repertoire of multifunctional CD4+ and CD8+ T cells. AIDS 2013; 27(13):2041-51.
    [9] Romain G, van Gulck E, Epaulard O, Oh S, Li D, Zurawski G, Zurawski S, Cosma A, Adam L, Chapon C, Todorova B, Banchereau J, Dereuddre-Bosquet N, Vanham G, Le Grand R, Martinon F. CD34-derived dendritic cells transfected ex vivo with HIV-Gag mRNA induce polyfunctional T-cell responses in nonhuman primates. European Journal of Immunology 2012; 42(8):2019-30.
    [10] Li D, Romain G, Flamar AL, Duluc D, Dullaers M, Li XH, Zurawski S, Bosquet N, Palucka AK, Le Grand R, O'Garra A, Zurawski G, Banchereau J, Oh S. Targeting self- and foreign antigens to dendritic cells via DC-ASGPR generates IL-10-producing suppressive CD4+ T cells. Journal of Experimental Medicine 2012; 209(1):109-21.

  • Division CORRELATES of PROTECTION

    Head of division : Hugo MOUQUET

    Hugo MOUQUETHugo Mouquet received his PhD in immunology from the University of Rouen (France), following his work on the characterization of T-cell and B-cell responses in an autoimmune disease of the skin called Pemphigus.

    He then moved to the Rockefeller University to perform his postdoctoral trainee in the lab headed by Michel C. Nussenzweig, where he studied B-cell antibody response to HIV-1 in humans.

    Since 2013, Hugo Mouquet is a group leader in the immunology department of the Institut Pasteur. His lab investigates the humoral response to viruses in humans and particularly, antibody response to HIV-1 in the context of the research performed at the VRI. Hugo Mouquet is the leader of the Correlates of Protection division of the VRI.


    Selected publicactions

    [1] Bruel T, Guivel-Benhassine F, Amraoui S, Malbec M, Richard L, Bourdic K, Donahue AD, Lorin V, Casartelli N, Noel N, Lambotte O, Mouquet H, Schwartz O. Elimination of HIV-1 infected cells by broadly neutralizing antibodies. Nature Communications 2016;7:10844.
    [2] Gardner MR, Kattenhorn LM, Kondur HR, von Schaewen M, Dorfman T, Chiang JJ, Haworth KG, Decker JM, Alpert MD, Bailey CC, Neale ES Jr, Fellinger CH, Joshi VR, Fuchs SP, Martinez-Navio JM, Quinlan BD, Yao AY, Mouquet H, Gorman J, Zhang B, Poignard P, Nussenzweig MC, Burton DR, Kwong PD, Piatak M Jr, Lifson JD, Gao G, Desrosiers RC, Evans DT, Hahn BH, Ploss A, Cannon PM, Seaman MS, Farzan M. AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges. Nature 2015; 519(7541):87-91.
    [3] McGuire AT, Dreyer AM, Carbonetti S, Lippy A, Glenn J, Scheid JF, Mouquet H, Stamatatos L. Antigen modification regulates competition of broad and narrow neutralizing HIV antibodies. Science 2014; 346(6215):1380-3.
    [4] Malbec M, Porrot F, Rua R, Horwitz J, Klein F, Halper-Stromberg A, Scheid J.F., Eden C, Mouquet H, Nussenzweig M.C., Schwartz O. Broadly neutralizing antibodies that inhibit HIV-1 cell-to-cell transmission. Journal of Experimental Medicine 2013; 210(13):2813-21.
    [5] Shingai M, Nishimura Y, Klein F, Mouquet H, Donau OK, Plishka R, Buckler-White A, Seaman M, Piatak M Jr, Lifson JD, Dimitrov DS, Nussenzweig MC, Martin MA. Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia. Nature 2013; 503(7475):277-80.
    [6] Klein F, Diskin R, Scheid JF, Gaebler C, Mouquet H, Georgiev I, Pancera M, Zhou T, Incesu RB, Zhongzheng Fu B, Gnanapragasam PNP, Oliveira TY, Seaman MS, Kwong PD, Bjorkman PJ and Nussenzweig MC. Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization. Cell 2013; 153(1):126-38.
    [7] Klein F, Halper-Stromberg A, Horwitz J, Kruell H, Scheid JF, Bournazos S, Mouquet H, Spatz, LA, Diskin R, Abadir A , Zang T, Dorner M, Billerbeck E, Labitt RN, Gaebler C, Marcovecchio P, Incesu R-B, Eisenreich TR, Bieniasz P, Seaman MS, Bjorkman PJ, Ravetch JV, Ploss A, Nussenzweig MC. HIV therapy by combinations of broadly neutralizing antibodies in humanized mice. Nature 2012; 492(7427):118-22.
    [8] Mouquet H, Scharf L, Euler Z, Liu K , Eden C, Scheid JF, Halper-Stromberg A, Spencer DIR, Seaman MS, Schuitemaker H, Feizi T, Nussenzweig MC, Bjorkman PJ. Complex-type N-glycan recognition by potent broadly-neutralizing HIV antibodies. PNAS 2012; 109(47):E3268-77.
    [9] Scheid JF, Mouquet H, Ueberheide B, Diskin R, Klein F, Oliveira TY, Pietzsch J, Fenyo D, Abadir A, Velinzon K, Hurley A, Myung S, Boulad F, Poignard P, Burton DR, Pereyra F, Ho DD, Walker BD, Seaman MS, Bjorkman PJ, Chait BT, Nussenzweig MC. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 2011; 333:1633-7.
    [10] Mouquet H, Scheid JF, Zoller MJ, Krogsgaard M, Ott RG, Shukair S, Artyomov MN, Pietzsch J, Connors M, Pereyra F, Walker BD, Ho DD, Wilson PC, Seaman MS, Eisen HN, Chakraborty AK, Hope TJ, Ravetch JV, Wardemann H, Nussenzweig MC. Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation. Nature 2010; 467:591-5.

    Anne-Sophie BEIGNON

    Anne Sophie BEIGNONMy long-term interest lies in inducing protective immunity against infectious diseases with vaccines and in understanding the modes of action of vaccines. I have explored a strategy of non-invasive administration of vaccines through the transcutaneous route and the requirement in terms of Ag form and type of adjuvant as a PhD student at IBMC in Strasbourg under the supervision of Sylviane Muller (1998-2002).

    Then I have studied the adjuvanticity of R848, a synthetic ligand of TLR7/8 involved in the detection of ssRNA viruses, on dendritic cells and decipher the molecular mechanisms of activation of plasmacytoid dendritic cells by HIV as a postdoctoral fellow at NYU; in NYC, USA, in the lab of Nina Bhardwaj (2002-2004).

    I have then advanced the development of candidate vaccines based on lentiviral vectors against Plasmodium/malaria and HIV/AIDS, including with pre-clinical trials in non-human primates, to assess their protective efficacy at Institut Pasteur, Paris, as a postdoctoral fellow (2005-2007) and then as a 2nd (2007-2010) and then a 1st class CNRS Junior Scientist (since 2011) in the lab of Pierre Charneau. I have joined the lab headed by Roger Le Grand in 2012 where I lead a small research group. I focus my research on elucidating the modes of action of vaccines, especially the molecular and cellular mechanisms that govern the induction and maintenance of secondary memory responses after prime/boost immunizations.

    I study the dynamic of and interactions between innate and adaptive responses as a function of the number of immunizations and of the vaccine schedule using a systems vaccinology approach, and particularly, after MVA immunizations of in non-human primates in the context of the research performed at the VRI.

    Anne-Sophie Beignon is PI in the Correlates of Protection division of the VRI.


    Selected publications

    [1] Pejoski D, Tchitchek N, Rodriguez Pozo A, Elhmouzi-Younes J, Yousfi-Bogniaho R, Rogez-Kreuz C, Clayette P, Dereuddre-Bosquet N, Lévy Y, Cosma A, Le Grand R, Beignon AS. Identification of vaccine-altered circulating B cell phenotypes using mass cytometry and a two-step clustering analysis. Journal of Immunology 2016; 196(11):4814-31.
    [2] Portilho DM, Frenandez J, Ringeard M, Machado AK, Boulay A, Mayer M, Müller-Trutwin M, Beignon AS, Kirchoff F, Nisole S, Arhel NJ. Endogeneous TRIM5a function is regulated by SUMOyltion and Nuclear sequestration for efficient sensing in dendritic cells. Cell Reports 2016; 14(2): 355-69.
    [3] Beignon AS, Le Grand R, Chapon C. In vivo imaging in NHP models of malaria: challenges, progress and outlooks. Parasitology International 2014; 63(1):206-15.
    [4] Coutant F, Sanchez David RY, Félix T, Boulay A, Caleechurn L, Souque P, Thouvenot C, Bourgouin C, Beignon AS*, Charneau P*. A Safe Nonintegrative Lentiviral Vector-Based Vaccine Provides Long-Term Sterile Protection Against Malaria. PLoS One 2012; 7(11): e48644. [*equal contribution]
    [5] Di Nunzio F, Félix T, Arhel NJ, Nisole S, Charneau P, Beignon AS. HIV-derived vectors for therapy and vaccination against HIV. Vaccine 2012; 30(15):2499-509.
    [6] Beignon AS, Mollier K, Liard C, Coutant F, Munier S, Rivière J, Souque P, Charneau P. Lentiviral vector-based prime/boost vaccination against AIDS: pilot study shows protection against Simian immunodeficiency virus SIVmac251 challenge in macaques. Journal of Virology 2009; 83(21):10963-74.
    [7] Beignon AS, McKenna K, Skoberne M, Manches O, DaSilva I, Kavanagh DG, Larsson M, Gorelick RJ, Lifson JD, Bhardwaj N. Endocytosis of HIV-1 activates plasmacytoid dendritic cells via Toll-like receptor-viral RNA interactions. Journal of Clinical Investigation 2005; 115(11):3265-75.

    Sylvain CARDINAUD

    Sylvain CARDINAUDSylvain Cardinaud obtained his PhD at the Pasteur Institute where he characterized antigens eliciting antiviral and anti-tumoral T-cell responses in humans. He demonstrated that mistranslation of the HIV genome naturally generates an abundant and cryptic source of antigens recognized by CD8 T-cells.

    As post-doctoral follow at the University of Berkeley (USA) and at the CIMI-Paris immunology center, he investigated immunological factors impacting on antigen processing and presentation of viral antigens.

    His findings underlined the major role of cryptic antigens in driving immune selection pressure on the virus in patients. His work also provided new insights into dendritic cells (DC) / HIV interactions and had implications in optimization of DC-based immunotherapy. In 2014, he worked at the Baylor Institute for Immunology Research (BIIR, USA), a key participant of the VRI, where he acquired a strong scientific expertise on DC-targeting vaccines.

    He brought this technology to the VRI. His group investigates the potency of DC-targeting vaccine for eliciting T- or B-cell responses in HIV therapeutic approach. He also PI an ANR program geared to the development of novel DC-based Ebola vaccines.
    Sylvain Cardinaud is PI in the Correlates of Protection division of the VRI.


    Present group’s members:

    • Jérôme Kervevan (PhD Student)
    • Aurélie Chaigneau (MSc student)


    Selected publications

    [1] Coulon PG, Richetta C, Rouers A, Blanchet FP, Urrutia A, Guerbois M, Piguet V, Theodorou I, Bet A, Schwartz O, Tangy F, Graff-Dubois S, Cardinaud S, Moris A. HIV-infected DC present endogenous MHC-II-restricted antigens to HIV-specific CD4 + T cells. Journal of Immunology 2016; in press.
    [2] van den Berg LM, Cardinaud S, van der Aar AM, Sprokholt JK, de Jong MA, Zijlstra-Willems EM, Moris A, Geijtenbeek TB. Langerhans Cell-Dendritic Cell Cross-Talk via Langerin and Hyaluronic Acid Mediates Antigen Transfer and Cross-Presentation of HIV-1. Journal of Immunology 2015; 195(4):1763-73.
    [3] Ayinde D, Bruel T, Cardinaud S, Porrot F, Prado JG, Moris A, and O. Schwartz. SAMHD1 Limits HIV-1 Antigen Presentation by Monocyte-Derived Dendritic Cells. Journal of Virology 2015; 89(14):6994-7006.
    [4] Bet A, Maze EA, Bansal A, Sterrett S, Gross A, Graff-Dubois S, Samri A, Guihot A, Katlama C, Theodorou I, Mesnard JM, Moris A, Goepfert PA, Cardinaud S. The HIV-1 Antisense Protein (ASP) induces CD8 T cell responses during chronic infection. Retrovirology 2015; 12:15.
    [5] Soria A, Boccara D, Chonco L, Yahia N, Dufossée M, Cardinaud S, Moris A, Liard C, Joulin-Giet A, Julithe M, Mimoun M, Combadière B, Perrin H. Long-term maintenance of skin immune system in a NOD-Scid IL2rγnull mouse model transplanted with human skin. Experimental Dermatoloy 2015; 23(11):850-2.
    [6] Posch W, Cardinaud S, Hamimi C, Fletcher A, Mühlbacher A, Loacker K, Eichberger P, Dierich MP, Pancino G, Lass-Flörl C, Moris A, Saez-Cirion A, Wilflingseder D. Antibodies attenuate the capacity of dendritic cells to stimulate HIV-specific CTLs. Journal of Allergy and Clinical Immunology 2012; 130(6):1368-74.
    [7] Rodriguez-Plata MT, Urrutia A, Cardinaud S, Buzón MJ, Izquierdo-Useros N, Prado JG, Puertas MC, Erkizia I, Coulon PG, Cedeño S, Clotet B, Moris A, Martinez-Picado J. HIV-1 capture and antigen presentation by dendritic cells: enhanced viral capture does not correlate with better T-cell activation. Journal of Immunology 2012; 188(12):6036-45.
    [8] Cardinaud S, Consiglieri G, Bouziat R, Urrutia A, Graff-Dubois S, Fourati S, Malet I, Guergnon J, Guihot A, Katlama C, Autran B, van Endert P, Lemonnier FA, Appay V, Schwartz O, Kloetzel PM, Moris A. CTL escape mediated by proteasomal destruction of an HIV-1 cryptic epitope. PLoS Pathogens 2011; 7(5):e1002049.
    [9] Blanchet FP, Moris A, Nikolic DS, Lehmann M, Cardinaud S, Stalder R, Garcia E, Dinkins C, Leuba F, Wu L, Schwartz O, Deretic V, Piguet V. Human immunodeficiency virus-1 inhibition of immunoamphisomes in dendritic cells impairs early innate and adaptive immune responses. Immunity 2010; 32(5):654-69.
    [10] Cardinaud S, Moris A, Février M, Rohrlich PS, Weiss L, Langlade-Demoyen P, Lemonnier FA, Schwartz O, Habel A. Identification of cryptic MHC I-restricted epitopes encoded by HIV-1 alternative reading frames. Journal of Experimental Medicine 2004; 199(8):1053-63

    Catherine CHAPON

    catherine chaponDr Catherine Chapon is Associate Professor in Biophysics at the Faculty of Medicine in the University of Paris-Sud 11 since 2009. She is in charge of the Imaging of Infection and Immunity core lab (L3i) in the IDMIT Infrastructure at the CEA at Fontenay-aux-Roses (http://www.idmitcenter.fr/). The national infrastructure for Infectious Disease Models and Innovative Therapies (IDMIT) is coordinated by CEA and is dedicated to preclinical evaluation of immune interventions, vaccines and preventive approaches of human infectious diseases.

    The goal of her research is to develop in vivo imaging approaches for studying host-pathogen interactions, immune responses to infections and to treatments, and for monitoring treatments and their impact on pathogen transmission and dissemination in non-human primate models of human diseases. The L3i core lab can provide multimodal in vivo imaging (optical imaging with confocal laser endomicroscopy, two-photon microscopy; and also Positron Emission Tomography from 2017), for in vivo monitoring of infections, host responses and treatments from whole body to cell resolution in non-human primates in Biosafety Safety Level 2 and 3 laboratories.


    Selected publications:

    [1] Salabert N, Todorova B, Martinon F, Boisgard R, Zurawski G, Zurawski S, Dereuddre-Bosquet N, Cosma A, Kortulewski T, Banchereau J, Levy Y, Le Grand R and Chapon C. Intradermal injection of an anti-Langerin-HIVGag fusion vaccine targets epidermal Langerhans cells in nonhuman primates and can be tracked in vivo. European Journal of Immunology 2016; 46(3):689-700.

    [2] Beignon AS, Le Grand R, Chapon C. In vivo imaging in NHP models of malaria: challenges, progress and outlooks. Parasitology International 2014; 63(1):206-15.

    [3] Epaulard O, Adam L, Poux C, Zurawski G, Salabert N, Rosenbaum P, Dereuddre-Bosquet N, Zurawski S, Flamar AL, Oh S, Romain G, Chapon C, Banchereau J, Levy Y, Le Grand R and Martinon F. Macrophage- and Neutrophil-Derived TNF-alpha Instructs Skin Langerhans Cells To Prime Antiviral Immune Responses. Journal of immunology 2014; 193(5):2416-2426.

    [4] Romain G, van Gulck E, Epaulard O, Oh S, Li D, Zurawski G, Zurawski S, Cosma A, Adam L, Chapon C, Todorova B, Banchereau J, Dereuddre-Bosquet N, Vanham G, Le Grand R and Martinon F. CD34-derived dendritic cells transfected ex vivo with HIV-Gag mRNA induce polyfunctional T-cell responses in nonhuman primates. European Journal of Immunology 2012; 42(8):2019-2030.

    Véronique GODOT

    To come

    Sophie HUE

    Sophie HUESophie HUE, MD, PhD is PU-PH (Professeur Universitaire-Praticien hospitalier) at the East Paris University (UPEC), France. She obtained her PhD from Paris V University (France) following her work on the role of NKG2D/MICA interaction in villous atrophy during coeliac disease.

    She then moved to Oxford University to perform her postdoctoral trainee in the lab headed by Fiona Powrie, where she studied the role of IL23 in inflammatory bowel disease.

    Since 2007, she works in the team 16, INSERM U955, part of the Labex Vaccine Research Institute (VRI). Her research is focus on the interaction between the commensal flora and the immune system in the gut and in the skin. Today, her work is focused on B cell responses in the gut of HIV infected patients. These studies are performed with the ultimate aim to provide novel insights for research on therapeutic and preventive vaccines.

    Sophie Hüe is PI in the Correlates of Protection division of the VRI


    Selected publications

    [1] Hotz C., Boniotto M., Guguin A, Surenaud M, Jean-Louis F., Tisserand P., Ortonne N., Hersant B., Bosc R., Poli F., Bonnabau H., Thiébaut R, Godot V., Wolkenstein P., Hocini H., Lévy Y. Hüe S. Intrinsic defect in keratinocyte function leads to inflammation in Hidradenitis suppurativa. Journal of Investigative Dermatology, 2016 in press.
    [2] Kök A, Hocqueloux L, Hocini H, Carrière M, Lefrou L, Guguin A, Tisserand P, Bonnabau H, Avettand-Fenoel V, Prazuck T, Katsahian S, Gaulard P, Thiébaut R, Lévy Y, Hüe S. Early initiation of combined antiretroviral therapy preserves immune function in the gut of HIV-infected patients. Mucosal Immunology 2015; 8(1):127-40.
    [3] Richert L.*, Hüe S.*, Hocini H., Raimbault M., Lacabaratz C., Surenaus M?, Wiedemann A., Tisserand P., Durier C., Salmon D., Lelièvre J.D., Chêne G., Thiebaut R. Lévy Y Cytokine and gene transcription profiles of immune responses elicited by HIV lipopeptide vaccine in HIV-negative volunteers * co-auteurs, AIDS. 2013 Jun 1;27(9):1421-31 * co-auteurs
    [4] Hüe S, Kared H, Mehwish Y, Mouhamad S, Balbo M, Levy Y. Notch activation on effector T cells increases their sensitivity to Treg cell-mediated suppression through upregulation of TGF-βRII expression. European Journal of Immunology 2012; 42(7):1796-803.
    [5] Zhang S, Hüe S, Sène S, Penfornis A, Bresson-Hadni S, Kantelip S, Caillat-Zucman S, A. Vuitton D MICA, NKG2D and TGF-beta expression in the liver of humans with alveolar echinococcosis: new actors in the tolerance to parasites. Journal of Infectious Diseases 2008; 197(9):1341-9.
    [6] Izcue A*, Hüe S*, Buonocore S, Arancibia-Cárcamo CV, Ahern PP, Iwakura Y, Maloy KJ, Powrie F. Interleukin-23 restrains regulatory T cell activity to drive T cell-dependent colitis. Immunity 2008; 28(4):559-70 * co-auteurs
    [7] Hüe S, Ahern P., Buonocore S. Kullberg M., Cua D.J., McKenzie B.S. Powrie F. Maloy K.J. IL-23 drives innate and T cell-mediated intestinal inflammation. Journal of Experimental Medicine 2006; 203(11):2473-83.
    [8] Uhlig HH, McKenzie BS, Hüe S, Thompson C, Joyce-Shaikh B, Stepankova R, Robinson N, Buonocore S, Tlaskalova-Hogenova H, Cua DJ, Powrie F. Differential Activity of IL-12 and IL-23 in Mucosal and Systemic Innate Immune Pathology. Immunity 2006; 25(2):309-18.
    [9] Hüe S, Mention JJ, Monteiro RC, Zhang SL, Cellier C, Schmitz J, Verkarre V, Fodil N, Bahram S, Cerf-Bensussan N, Caillat-Zucman S. A direct role for NKG2D/MICA interaction in villous atrophy during celiac disease. Immunity 2004; 21(3):367-77.

    Roger LE GRAND

    Roger LE GRANDRoger Le Grand has been head of IMmunology of Viral and Auto-immune diseases department since 2015, and formerly the Department of Immuno-virology (SIV) since 2008. He is the IDMIT, infrastructure for Infectious Diseases Models and innovative Therapies, chief executive since 2012.

    Dr. Le Grand’s research group is currently developing NHP models for HIV, HBV, dengue, human influenza, Chikungunya, Chlamydia, Pertussis and new emerging diseases. Dr Le Grand is particularly interested in host-pathogen interactions and the prevention of viral transmission.

    His researches have generated more than 150 referenced peer-reviewed publications. He has been working as an expert for several French national research agencies, the French government, the European TRANSVAC program, the Bill and Melinda Gates Foundation and the WHO.

    The goal of his research is to study host response to infections with the aim to understand basic mechanisms of immunology and develop new prevention strategies of human infectious diseases. His work is mainly based on the use of preclinical models, including non-human primate models of human diseases, and the development of advanced technologies in cytometry and in vivo imaging, with a continuing effort to translate findings in experimental models to the clinical practice.

    Roger Le Grand is PI in the Correlates of Protection division of the VRI


    Selected publications

    [1] Bernard-Stoecklin S, Gommet C, Corneau AB, Guenounou S, Torres C, Dejucq-Rainsford N, Cosma A, Dereuddre-Bosquet N and Le Grand R. Semen CD4+ T cells and macrophages are productively infected at all stages of SIV infection in macaques. PLoS Pathogens 2013; 9(12):e1003810.
    [2] Bruel T, Dupuy S, Demoulins T, Rogez-Kreuz C, Dutrieux J, Corneau A, Cosma A, Cheynier R, Dereuddre-Bosquet N, Le Grand R and Vaslin B. Plasmacytoid dendritic cell dynamics tune interferon-alfa production in SIV-infected cynomolgus macaques. PLoS Pathogens 2014; 10(1):e1003915.
    [3] Damouche A, Lazure T, Avettand-Fenoel V, Huot N, Dejucq-Rainsford N, Satie AP, Melard A, David L, Gommet C, Ghosn J, Noel N, Pourcher G, Martinez V, Benoist S, Bereziat V, Cosma A, Favier B, Vaslin B, Rouzioux C, Capeau J, Muller-Trutwin M, Dereuddre-Bosquet N, Le Grand R, Lambotte O and Bourgeois C. Adipose Tissue Is a Neglected Viral Reservoir and an Inflammatory Site during Chronic HIV and SIV Infection. PLoS Pathogens 2015; 11(9):e1005153.
    [4] Epaulard O, Adam L, Poux C, Zurawski G, Salabert N, Rosenbaum P, Dereuddre-Bosquet N, Zurawski S, Flamar AL, Oh S, Romain G, Chapon C, Banchereau J, Levy Y, Le Grand R and Martinon F. Macrophage- and Neutrophil-Derived TNF-alpha Instructs Skin Langerhans Cells To Prime Antiviral Immune Responses. Journal of immunology; 2014, 193(5):2416-2426.
    [5] Le Grand R, Bosquet N, Dispinseri S, Gosse L, Desjardins D, Shen X, Tolazzi M, Ochsenbauer C, Saidi H, Tomaras G, Prague M, Barnett SW, Thiebaut R, Cope A, Scarlatti G and Shattock RJ. Superior efficacy of an HIV vaccine combined with ARV prevention in SHIV challenged non-human primates. Journal of Virology 2016; 90(11):5315-28.
    [6] Li D, Romain G, Flamar AL, Duluc D, Dullaers M, Li XH, Zurawski S, Bosquet N, Palucka AK, Le Grand R, O'Garra A, Zurawski G, Banchereau J and Oh S. Targeting self- and foreign antigens to dendritic cells via DC-ASGPR generates IL-10-producing suppressive CD4+ T cells. Journal of Experimental Medicine 2012; 209(1):109-121.
    [7] Moog C, Dereuddre-Bosquet N, Teillaud JL, Biedma ME, Holl V, Van Ham G, Heyndrickx L, Van Dorsselaer A, Katinger D, Vcelar B, Zolla-Pazner S, Mangeot I, Kelly C, Shattock RJ and Le Grand R. Protective effect of vaginal application of neutralizing and nonneutralizing inhibitory antibodies against vaginal SHIV challenge in macaques. Mucosal Immunology 2014; 7(1):46-56.
    [8] Romain G, van Gulck E, Epaulard O, Oh S, Li D, Zurawski G, Zurawski S, Cosma A, Adam L, Chapon C, Todorova B, Banchereau J, Dereuddre-Bosquet N, Vanham G, Le Grand R and Martinon F. CD34-derived dendritic cells transfected ex vivo with HIV-Gag mRNA induce polyfunctional T-cell responses in nonhuman primates. European journal of immunology 2012; 42(8):2019-2030.
    [9] Salabert N, Todorova B, Martinon F, Boisgard R, Zurawski G, Zurawski S, Dereuddre-Bosquet N, Cosma A, Kortulewski T, Banchereau J, Levy Y, Le Grand R and Chapon C. Intradermal injection of an anti-Langerin-HIVGag fusion vaccine targets epidermal Langerhans cells in nonhuman primates and can be tracked in vivo. European journal of immunology 2016; 46(3):689-700.
    [10] Skold AE, Hasan M, Vargas L, Saidi H, Bosquet N, Le Grand R, Smith CI and Spetz AL. Single-stranded DNA oligonucleotides inhibit TLR3-mediated responses in human monocyte-derived dendritic cells and in vivo in cynomolgus macaques. Blood 2012; 120(4):768-777.

    Frédéric MARTINON

    frederic martinonDr Frédéric Martinon has a strong background on immunology and 25 years of experience on immune responses to vaccines in animal models. He is currently working at the Immunology of Viral and Auto-immune diseases department (ImVA, Inserm U1184), Commissariat à l’Energie Atomique, Fontenay-aux-Roses, with a CR1 position at the Inserm. He completed his Ph.D. degree in Immunology from the University Pierre et Marie Curie Paris 6. After a postdoc at the NIH (Bethesda, USA) on T cell activation, he started to study anti-HIV vaccine candidates in the non-human primate models of AIDS, at the Cochin Institute (Paris) then at the CEA (Fontenay-aux-Roses).

    Since ten years he is the leader of the “Basic mechanisms of anti-viral vaccination” group in the ImVA department and drives the scientific projects of students and post-docs. He has published more than 40 research articles. In the recent past year, he focused on the early events occurring at the injection sites of vaccines at the cellular and molecular levels. He studied the role of adjuvants on the local inflammation and the influence of the antigen-expressing vectors on the orientation of the adaptive immune responses.

    He teaches at the University Pierre et Marie Curie Paris 6, at the University of Tours and at the University of Paris-Est Créteil Val de Marne for the Master 2 of Vaccinology organized by the VRI. He participated to several National and European projects as principal investigator or associated partner. He is the member of the French Society of Immunology. He is the member of the network "Nonhuman primate models for AIDS and viral hepatitis" at the ANRS. He is the member of the CoReVac network of multidisciplinary vaccine researches.


    Selected publications

    [1] Martinon F, Brochard P, Ripaux M, Delache B, Auregan G, Vaslin B, Le Grand R: Improved protection against simian immunodeficiency virus mucosal challenge in macaques primed with a DNA vaccine and boosted with the recombinant modified vaccinia virus Ankara and recombinant Semliki Forest virus. Vaccine 2008, 26:532-545.

    [2] Bourry O, Brochard P, Souquiere S, Makuwa M, Calvo J, Dereuddre-Bosquet N, Martinon F, Benech H, Kazanji M, Le Grand R: Prevention of vaginal simian immunodeficiency virus transmission in macaques by postexposure prophylaxis with zidovudine, lamivudine and indinavir. AIDS 2009; 23:447-454.

    [3] Martinon F, Kaldma K, Sikut R, Culina S, Romain G, Tuomela M, Adojaan M, Mannik A, Toots U, Kivisild T,Morin J, Brochard P, Delache B, Tripiciano A, Ensoli F, Stanescu I, Le Grand R and Ustav M: Persistent immune responses induced by a human immunodeficiency virus DNA vaccine delivered in association with electroporation in the skin of nonhuman primates. Human Gene Therapy 2009; 20:1291-1307.

    [4] Romain G, van Gulck E, Epaulard O, Oh S, Li D, Zurawski G, Zurawski S, Cosma A, Adam L, Chapon C, Todorova B, Banchereau J, Dereuddre-Bosquet N, Vanham G, Le Grand R and Martinon F: CD34-derived dendritic cells transfected ex vivo with HIV-Gag mRNA induce polyfunctional T-cell responses in nonhuman primates. European Journal of Immunology 2012; 42:2019-2030.

    [5] Borggren M, Vinner L, Andresen BS, Grevstad B, Repits J, Melchers M, Elvang TL, Sanders RW, Martinon F, Dereuddre-Bosquet N, Bowles E J, Stewart-Jones G, Biswas P, Scarlatti G, Jansson M, Heyndrickx L, Le Grand R and Fomsgaard A: Optimization of HIV-1 envelope DNA vaccine candidates within three different animal models, guinea pigs, rabbits and cynomolgus macaques. Vaccines 2013; 1:305-327.

    [6] Epaulard O, Adam L, Poux C, Zurawski G, Salabert N, Rosenbaum P, Dereuddre-Bosquet N, Zurawski S, Flamar AL, Oh S, Romain G, Chapon C, Banchereau J, Levy Y, Le Grand R and Martinon F: Macrophage- and Neutrophil-Derived TNF-alpha Instructs Skin Langerhans Cells To Prime Antiviral Immune Responses. Journal of Immunology 2014; 193:2416-2426.

    [7] Dereuddre-Bosquet N, Baron ML, Contreras V, Gosse L, Mangeot I, Martinon F, Yousfi R, Clayette P, Levy Y, Le Grand R: HIV specific responses induced in nonhuman primates with ANRS HIV-Lipo-5 vaccine combined with rMVA-HIV prime or boost immunizations. Vaccine 2015; 33:2354-2359.

    [8] Adam L, Rosenbaum P, Cosma A, Le Grand R, Martinon F: Identification of skin immune cells in non-human primates. Journal of Immunological Methods 2015; 426:42-49.

    [9] Flamar AL, Contreras V, Zurawski S, Montes M, Dereuddre-Bosquet N, Martinon F, Banchereau J, Le Grand R, Zurawski G, Levy Y: Delivering HIV Gagp24 to DCIR Induces Strong Antibody Responses In Vivo. PLoS One 2015; 10:e0135513.

    [10] Salabert N, Todorova B, Martinon F, Boisgard R, Zurawski G, Zurawski S, Dereuddre-Bosquet N, Cosma A, Kortulewski T, Banchereau J, Levy Y, Le Grand R and Chapon C: Intradermal injection of an anti-Langerin-HIVGag fusion vaccine targets epidermal Langerhans cells in nonhuman primates and can be tracked in vivo. European Journal of Immunology 2016; 46:689-700.

    Elisabeth MENU

    Elisabeth MENUElisabeth Menu received her PhD in 1990 in reproductive immunology from the University Paris 6, France in Gérard Chaouat laboratory.

    After a postdoctoral training at the Dana Farber Cancer Institute (Harvard medical School, Boston, USA) on human T cell activation, she started to work in 1994 on the control of HIV-1 transmission at the materno-fetal interface in collaboration with teams in Africa and Asia. She has a permanent position at the INSERM in 1998.

    From 2000 to 2015 she was leading a team in the unit of Françoise Barré-Sinoussi at the Institut Pasteur, Paris and since 2010 she is an INSERM associate professor (DR2). She was nominated Institut Pasteur group leader in 2015.

    She recently joined with her group the ImVA research center directed by Roger Le Grand at the CEA Fontenay-aux-Roses in the framework of a collaboration with the Institut Pasteur.

    The main expertise of her group is on mucosal immunity and more specifically at the female genital tract level in the context of the control of HIV-1/SIV infection/transmission. Her work highlights the crucial role of innate immunity in the control of the early step of HIV-1 infection at mucosal level. The research developped at the VRI focuses on the mucosal vaccine immune responses in the female reproductive tract and particulary on the role of the seminal plasma and the inflammation on these local immune responses.

    Elisabeth Menu is PI in the Correlates of Protection division of the VRI.


    Selected publications

    [1] Menu E., M’bopi Kéou FX, Lagaye S, Pissard S, Mauclère P, Scarlatti G, Martin J, Goossens M, Chaouat G, Barré-Sinoussi F and the European Network for in utero transmission of HIV-1. Selection of maternal HIV-1 variants in human placenta. Journal of Infectious Diseases 1999; 179:44-51.
    [2] Lagaye S, Derrien, M, Menu E, Coïto C, Tresoldi E, Mauclère P, Scarlatti G, Chaouat G, Barré-Sinoussi F, & Bomsel M, and the European Network for the study of in utero transmission of HIV-1. Cell to cell contact results in a selective translocation of maternal HIV-1 quasispecies across a trophoblastic barrier by both transcytosis and infection. Journal of Virology 2001; 75:4780-4791.
    [3] Derrien M, Faye A, Dolcini G, Chaouat G, Barré-Sinoussi F, Menu E. Impact of the placental cytokine-chemokine balance on the regulation of cell-cell contact-induced HIV-1 translocation across a trophoblastic barrier in vitro. Journal of Virology 2005; 79:12304-12310.
    [4] Marlin R, Nugeyre MT, de Truchis C, Berkane N, Gervaise A, Barré-Sinoussi F, Menu E. Antigen-Presenting Cells represent targets for R5 HIV-1 infection in the first trimester pregnancy uterine mucosa. PloS One 2009; 4(6):e5971.
    [5] Marlin R, Nugeyre MT, Duriez M, Cannou C, Le Breton A, Berkane N, Barré-Sinoussi F, and Menu E. Decidual soluble factors participate in the control of HIV-1 infection at the maternofetal interface. Retrovirology 2011; 8:58.
    [6] Marlin R, Duriez M, Berkane N, de Truchis C, Madec Y, Rey-Cuille MA, Cummings JS, Cannou C, Quillay H, Barré-Sinoussi F, Nugeyre MT, Menu E. Dynamic shift from CD85j/ILT-2 to NKG2D NK receptor expression pattern on human decidual NK during the first trimester of pregnancy. PloS One 2012; 7(1):e30017.
    [7] Duriez M, Quillay H, Madec Y, El Costa H, Cannou C, Marlin R, de Truchis C, Rahmati M, Barré-Sinoussi F, Nugeyre MT, and Menu E. Human decidual macrophages and NK cells differentially express Toll-like receptors and display distinct cytokine profiles upon TLR stimulation. Frontiers in Microbiology 2014; 15(316):1-14.
    [8] Quillay H, El Costa H, Marlin R, Duriez M, Cannou C, Chrétien F, Fernandez H, Lebreton A, Ighil J, Schwartz O, Barré-Sinoussi F, Nugeyre MT, Menu E. Distinct endometrial and decidual macrophage characteristics and regulation of their permissivity to HIV-1 infection by SAMHD1. Journal of Virology 2015; 89(2):1329-39.
    [9] El Costa H, Quillay H, Cannou C, Duriez M, De Truchis C, Le Breton A, Rahmati M, Julien Ighil, Barré-Sinoussi F, Nugeyre MT, Menu E. The Local Environment and Innate Receptors Orchestrate Mucosal Macrophage Differentiation and Substantially Inhibit HIV-1 Replication. Mucosal Immunology 2016; 9(3):634-46.

    Christiane MOOG

    Christiane MOOGChristiane Moog (PhD 1990, in Immunochemistry at University Louis Pasteur, Strasbourg; post-doc at DKFZ, Heidelberg, Germany) was hired by Synthélabo to develop the screening of anti-HIV compounds at the Institute of Virology in Strasbourg. The team was involved in numerous antiviral development to increase efficacy, limit resistance and study synergistic effects of antiviral compounds.

    Christiane Moog further joined INSERM, developed her own group and created the neutralizing antibody plate-form in which experiments are performed under GcLP (good clinical laboratory practices) conditions. She notably participated in the standardization of neutralization assays and is a member of various coordinated actions: proficiency testing (coordinated by D. Montefiori), NeutNet (coordinated by G. Scarlatti) and Europrise (FP6-EC).

    She is partner of several HIV vaccine projects: ANRS (Vac 02 to Vac 18), VRI LabEx (MUCOVAC), European projects (EuroVacI and EuroVacII from FP5-EC, EuroNeut41 from FP7-EC and EHVA from Horizon 2020). She was pioneer in investigating the various Fc-mediated inhibitory functions of non-neutralizing HIV-1 specific antibodies to be induced in addition or as alternative to neutralizing antibodies with the aim to develop new vaccination strategies.

    Christiane Moog is PI in the Correlates of Protection division of the VRI.


    Selected publicactions

    [1] Santra S, Tomaras GD, Warrier R, Nicely NI, Liao HX, Pollara J, Liu P, Alam SM, Zhang R, Cocklin SL, Shen X, Duffy R, Xia SM, Schutte RJ, Pemble Iv CW, Dennison SM, Li H, Chao A, Vidnovic K, Evans A, Klein K, Kumar A, Robinson J, Landucci G, Forthal DN, Montefiori DC, Kaewkungwal J, Nitayaphan S, Pitisuttithum P, Rerks-Ngarm S, Robb ML, Michael NL, Kim JH, Soderberg KA, Giorgi EE, Blair L, Korber BT, Moog C, Shattock RJ, Letvin NL, Schmitz JE, Moody MA, Gao F, Ferrari G, Shaw GM, Haynes BF. Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques. PLoS Pathogens 2015; 11(8):e1005042.
    [2] Crespillo S, Camara-Artigas A, Casares S, Morel B, Cobos ES, Mateo PL, Mouz N, Martin CE, Roger MG, El Habib R, Su B, Moog C, Conejero-Lara F. Single-chain protein mimetics of the N-terminal heptad-repeat region of gp41 with potential as anti-HIV-1 drugs. PNAS 2014; 111:18207-18212.
    [3] Su B, Lederle A, Laumond G, Ducloy C, Schmidt S, Decoville T, Moog C. Broadly neutralizing antibody VRC01 prevents HIV-1 transmission from plasmacytoid dendritic cells to CD4 T lymphocytes. Journal of Virology 2014; 88:10975-81.
    [4] Peressin M, Proust A, Schmidt S, Su B, Lambotin M, Biedma ME, Laumond G, Decoville T, Holl V, Moog C. Efficient transfer of HIV-1 in trans and in cis from Langerhans dendritic cells and macrophages to autologous T lymphocytes. AIDS 2014; 28, 667-677.
    [5] Moog C, Dereuddre-Bosquet N, Teillaud JL, Biedma M. E., Holl V, VanHam G., Heyndrickx L, Van Dorsselaer A., Katinger D., Vcelar B, Zolla-Pazner S., Mangeot I, Kelly C, Shattock R., Le Grand R., Protective effect of vaginal application of neutralizing and non-neutralizing inhibitory antibodies against vaginal SHIV challenge in macaques Mucosal Immunology 2014; 7(1):46-56.
    [6] Su B., Ke X., Lederle A., Peressin M., Biedma M., Laumond G., Schmidt S., Decoville T., Proust A., Lambotin M., Holl V., Moog C. Neutralizing antibodies inhibit HIV-1 transfer from primary dendritic cells to autologous CD4 T-lymphocytes Blood 2012; 120:3708-17.
    [7] Heyndrickx L, Heath A, Sheik-Khalil E, Alcami J, Bongertz V, Jansson M, Malnati M, Montefiori D, Moog C, Morris L, Osmanov S, Polonis V, Ramaswamy M, Sattentau Q, Tolazzi M, Schuitemaker H, Willems B, Wrin T, Fenyö EM, Scarlatti G. PL International Network for Comparison of HIV Neutralization Assays: The NeutNet Report II PloS One 2012; 7(5):e36438.
    [8] Holl V., M. Peressin M, Schmidt S., Decoville T., Zolla-Pazner S., Aubertin A.M. and Moog C. Efficient inhibition of HIV-1 replication in human immature monocyte-derived dendritic cells by purified anti-HIV-1 IgG without induction of maturation. Blood 2006; 107:4466-4474.
    [9] Holl V., M. Peressin M, Decoville T., Schmidt S., Zolla-Pazner S., Aubertin A.M. and Moog C. “Non-neutralizing” antibodies are able to inhibit HIV-1 replication in macrophages and immature dendritic cells. Journal of Virology 2006; 80:6177-6181.
    [10] C. Moog, H. Fleury, I. Pellegrin, A. Kirn and A.M. Aubertin Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodificiency virus type 1-infected individuals. Journal of Virology 1997; 71:3734-3741.

    Michaela MULLER-TRUTWIN

    Michaela MULLER TRUTWINMichaela Müller-Trutwin studied Biology at the University in Bonn and Frankfurt, Germany, and obtained her PhD from Paris University, France in the Barré-Sinoussi lab. She worked at Research Institutes in West and Central Africa, in particular with Institut Pasteur in Senegal and in Central African Republic and the CIRMF in Gabon. In 2009, she obtained the position of Associate Professor at Institut Pasteur.

    In 2014 she was appointed head of the Unit “HIV, inflammation and persistence” at Institut Pasteur. As Dean, she build up and directed the Pasteur-Paris University International PhD Program from 2008 to 2013. Among other duties, she serves in the Steering Committee of the Center for Innovative Therapies for infectious Disease models (IDMIT).

    Her research contributed to the discovery and genetic characterization of several HIV and SIV viruses in Africa and South-East Asia. These studies were essential in the early times to better understand the epidemic of HIV-1, to improve clinical monitoring and for vaccine candidate development.

    Today, her work is focused on deciphering the early host innate immune responses which are involved in the control of viral reservoirs in tissues, in particular those playing a major role in the induction and education of adaptive immune responses, i.e. secondary lymphoid organs.

    These studies are performed with the ultimate aim to provide crucial novel insights for research on therapeutic and preventive approaches in humans.
    Michaela Müller-Trutwin is PI in the Correlates of Protection division of the VRI.


    Selected publications

    [1] Simon F, Mauclère P, Roques P, Loussert-Ajaka I, Müller-Trutwin MC, Saragosti S, Georges-Courbot MC, Barré-Sinoussi F & Brun-Vézinet F. Identification of a new Human Immunodeficiency virus type 1 distinct from group M and group O. Nature Medicine 1998; 4: 1032-1037.
    [2] Müller-Trutwin MC & Barré-Sinoussi F. Towards improvements in molecular tools for diagnosis and managment of HIV infections. Lancet 1999; 354: 1660-1662.
    [3] Konfeld C, Ploquin M, I Pandrea, A. Faye, R Onanga, C Apetrei, V Poaty, P Rouquet, J Estaquier, L Mortara, JF Desoutter, C Butor, R Legrand, P Roques, F Simon, F Barré-Sinoussi, OM Diop & MC Müller-Trutwin. Anti-inflammatory Profiles during Primary SIVagm Infection are Associated with Protection against AIDS. Journal of Clinical Investigation 2005; 115 (4): 1082-1091.
    [4] Schindler M, Münch J, Kutsch O, Li H, Santiago ML, Bibollet-Ruche F, Müller-Trutwin MC, Novembre F, Peeters M, Bailes L, Roques P, Courgnaud C, Silvestri G, Hahn B & Kirchhoff F, 2006. Nef of HIV-2 and SIV, but not of HIV-1, downregulate CD3 and mediate suppression of T cell activation. Cell 2006; 125(6):1055-67.
    [5] Sodora DL, Allan JS, Apetrei C, Brenchley JM, Douek DC, Else JG, Estes JD, Hahn BH, Hirsch VM, Kaur A, Kirchhoff F, Muller-Trutwin M, Pandrea I, Schmitz JE, Silvestri G. Toward an AIDS vaccine: lessons from natural simian immunodeficiency virus infections of African nonhuman primate hosts. Nature Medicine 2009; 15(8):861-5.
    [6] Jacquelin B., Mayau V, Targat B, Liovat AS, Kunkel D, Petitjean G, Dillies MA, Roques P, Butor C, Giavedoni LD, Lebon P, Barré-Sinoussi F, Benecke A & Müller-Trutwin M. Strong but Rapidly Controlled Interferon Type I Response in Nonpathogenic SIV Infection of African Green Monkeys. Journal of Clinical Investigation 2009; 119(12):3544-55.
    [7] Ploquin MJ, Jacquelin B, Jochems SP, Barré-Sinoussi F & Müller-Trutwin MC. Innate immunity in the control of HIV/AIDS: recent advances and open questions. AIDS 2012; 26(10):1269-79.
    [8] Jacquelin B, G. Petitjean, D. Kunkel, A-S. Liovat, S.P. Jochems, K.A. Rogers, M.J. Ploquin, F. Barré-Sinoussi, N. Dereuddre-Bosquet, P. Lebon, R. Le Grand, F. Villinger & M. Müller-Trutwin. Innate Immune Responses and Rapid Control of Inflammation in African Green Monkeys Treated or not with Interferon-Alpha during Primary SIVagm Infection. PLoS Pathogens 2014; 10(7):e10042412014
    [9] Rokx C, DD. Richman, M Müller-Trutwin, G Silvestri, J van Lunzen, S Khoo, M Lichterfeld, M Altfeld, CF Perno, PW. Hunt, P Mallon, J Rockstroh, AL. Pozniak, CA.B. Boucher. Highlights of the Second European Roundtable on the Future Management of HIV. Journal of Virus Eradication 2015; 1: 211–220.

  • Division VIROLOGY

    Head of division : Constance DELAUGERRE

    Constance DELAUGERREConstance Delaugerre completed her PharmD 1997 and has specialized in HIV clinical research. She defended her PhD thesis in 2003 on the “Molecular mechanisms of HIV drug resistance to antiretroviral drugs”. Associate Professor since 2007 in Clinical Virology in Saint Louis Hospital and Inserm U941, Paris Diderot University, France.

    Research fields are (1) HIV viral reservoir dynamics in primary HIV infection and during lymhoma/stem cell transplantation and (2) antiretroviral pre-exposition prevention. She coordinates virological studies in ANRS and Vaccine Research Institute (VRI) trials: EASIER, OPTIMAL, REFLATE TB I & II, TREVE, LIGHT, DALIA-2 and IPERGAY.

    She is the chairwoman of the Scientific and Medical Committee of Sidaction since 2012.

    Constance Delaugerre is the leader of the Virology division of the VRI.


    Selected publications

    [1] Menkova-Garnier I, Hocini H, Foucat E, Tisserand P, Bourdery L, Delaugerre C, Benne C, Lévy Y, Lelièvre JD. P2X7 Receptor Inhibition Improves CD34 T-Cell Differentiation in HIV-Infected Immunological Nonresponders on c-ART. PLoS Pathogens 2016;12(4):e1005571.
    [2] Molina JM, Capitant C, Spire B, Pialoux G, Cotte L, Charreau I, Tremblay C, Le Gall JM, Cua E, Pasquet A, Raffi F, Pintado C, Chidiac C, Chas J, Charbonneau P, Delaugerre C, Suzan-Monti M, Loze B, Fonsart J, Peytavin G, Cheret A, Timsit J, Girard G, Lorente N, Préau M, Rooney JF, Wainberg MA, Thompson D, Rozenbaum W, Doré V, Marchand L, Simon MC, Etien N, Aboulker JP, Meyer L, Delfraissy JF; ANRS IPERGAY Study Group. On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection. New England Journal of Medicine 2015; 373(23):2237-46.
    [3] Ghosn J, Delaugerre C. Can we avoid treatment interruption studies in the search for an HIV cure? AIDS 2015; 29(12):1575-7.
    [4] Gallien S, Charreau I, Nere ML, Mahjoub N, Simon F, de Castro N, et Delaugerre C. Archived HIV-1 DNA resistance mutations to rilpivirine and etravirine in successfully treated HIV-1-infected individuals pre-exposed to efavirenz or nevirapine. Journal of Antimicrobial Chemotherapy 2015;70(2): 562-565.
    [5] Delaugerre C, Ghosn J, Lacombe JM, Pialoux G, Cuzin L, Launay O, et al. Significant Reduction in HIV Virologic Failure During a 15-Year Period in a Setting With Free Healthcare Access. Clinical Infectious Diseases 2015; 60(3):463-72.
    [6] Grinsztejn B, De Castro N, Arnold V, Veloso VG, Morgado M, Pilotto JH, Brites C, Madruga JV, Barcellos NT, Santos BR, Vorsatz C, Fagard C, Santini-Oliveira M, Patey O, Delaugerre C, Chêne G, Molina JM; for the ANRS 12 180 Reflate TB study group. Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial. Lancet Infectious Diseases 2014; 14(6):459-67
    [7] Delaugerre C, Gallien S, Flandre P, Mathez D, Amarsy R, Ferret S, Timsit J, Molina J-M, De Truchis P. Impact of low-level-viremia on HIV-1 drug-resistance evolution among antiretroviral treated-patients. PLoS ONE 2012; 7:e36673.
    [8] Gallien S, Delaugerre C, Charreau I, Braun J, Boulet T, Barrail-Tran A, De Castro N, Molina J-M, Kuritzkes DR. Emerging integrase inhibitor resistance mutations in raltegravir-treated HIV-1-infected patients with low-level viremia. AIDS 2011; 25:665–669.
    [9] Delaugerre C, De Oliveira F, Lascoux-Combe C, Plantier J-C, Simon F. HIV-1 group N: travelling beyond Cameroon. Lancet 2011; 378:1894.
    [10] Ghosn J*, Delaugerre C*, Flandre P, Galimand J, Cohen-Codar I, Raffi F, Delfraissy J-F, Rouzioux C, Chaix M-L. Polymorphism in Gag gene cleavage sites of HIV-1 non-B subtype and virological outcome of a first-line lopinavir/ritonavir single drug regimen. PLoS ONE 2011; 6:e24798.

  • Division CLINICAL DEVELOPMENT

    Head of division : Geneviève CHENE

    Geneviève CHENEGeneviève Chêne, MD PhD, is professor in clinical epidemiology and public health at Bordeaux University since 1999. Her main areas of interest are: Translational epidemiology and public health, clinical epidemiology, e-learning, infectious diseases, Alzheimer and neuro-degenerative diseases.

    As a researcher, between 2003 and 2015, Geneviève has led an Inserm research team on clinical research, than on “HIV infections and associated morbidity” and a Clinical Trials Unit as a platform of excellence for national and international studies in HIV/AIDS sponsored by the National Agency for Research on AIDS and viral hepatitis (ANRS).

    Most cited works showed how the efficacy and safety of antiretroviral therapy can be durable over the long term or contributed to the development of epidemiological and statistical innovations needed to conceive or analyse clinical trials or large cohorts. Since 2010, as co- principal investigator of Memento, a national cohort of 2,300 participants recruited in memory clinics, she is actively transferring know-how in other areas than HIV (Inserm Unit 1219).

    Since 2014, as head of an international platform for international clinical trials (“EUCLID”), funded by the investments for the future through F-CRIN infrastructure, she is involved in the support and coordination of trials for the evaluation of innovative strategies in the field of vaccines (HIV, viral hepatitis, Ebola virus), neuro-degenerative diseases, obesity/metabolism or medical devices. This platform is one component of the Clinical Epidemiology Center (CIC-EC7, Inserm, CHU de Bordeaux) that she is leading since 2008. At Bordeaux University hospital (CHU Bordeaux), she is also head of the public health department since 2011.

    As a professor of public health, Geneviève Chêne teaches clinical epidemiology at the Bordeaux School of Public Health (Univ Bordeaux) where she initiated an international distant-learning program in epidemiology and clinical research (more than 4500 students since 2001).
    In 2013, she was nominated in the “Comité des Sages” by the Prime Minister for the preparation of the National Strategy for Health. Geneviève Chêne is currently the Director of the Public Health Multi-Organization Thematic Institute of the French National Alliance for Life Sciences and Health (Aviesan and Inserm, Paris) and, since 2013, serves as vice-chair of the scientific evaluation committee of the National Program for Clinical Research (PHRC).
    Geneviève Chêne is one of the leaders of the Clinical Development division of the VRI.


    Selected publications

    [1] Richert L, Doussau A, Lelièvre JD, Arnold V, Rieux V, Bouakane A, Lévy Y, Chêne G, Thiébaut R; Vaccine Research Institute (VRI). Accelerating clinical development of HIV vaccine strategies: methodological challenges and considerations in constructing an optimised multi-arm phase I/II trial design. Trials 2014; 15:68.
    [2] Lévy Y, Thiébaut R, Montes M, (...), Chêne G, Banchereau J, Palucka K. Dendritic cell-based therapeutic vaccine elicits polyfunctional HIV-specific T-cell immunity associated with control of viral load. European Journal of Immunology 2014; 44(9):2802-10.
    [3] Raffi F, Babiker AG, Richert L, (…), Chêne G, Pozniak A, for the NEAT 001/ANRS 143 Study Group. Ritonavir-boosted darunavir combined with raltegravir or tenofovir-embticitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial. Lancet 2014; 384(9958):1942-51.
    [4] Grinsztejn B, De Castro N, Arnold V, (…), Chêne G, Molina JM; ANRS 12 180 Reflate TB study group. Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial. Lancet Infectious Diseases 2014; 14(6):459-67.
    [5] Morlat P, Roussillon C, Henard S, (…), Chêne G; ANRS EN20 Mortalité 2010 Study Group. Causes of death among HIV-infected patients in France in 2010 (national survey): trends since 2000. AIDS. 2014; 28(8):1181-91.
    [6] L. Richert, S. Hue, H Hocini, (…), J-D. Lelièvre, G. Chêne, R. Thiébaut, Y. Lévy for the ANRS Vaccine Network / Vaccine Research Institute. Cytokine and Gene Transcription Profiles of Immune Responses Elicited by HIV Lipopeptide Vaccine in HIV-Negative Volunteers. AIDS 2013; 27:1421-1431.
    [7] L. Wittkop, HF Günthard, F. de Wolf, (…), G. Chêne; EuroCoord-CHAIN study group. Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV. Lancet Infectious Diseases 2011; 11:363-71.
    [8] Y. Lévy, R. Thiébaut, M-L. Gougeon, (…), C. Lane, J-F. Delfraissy, I. Sereti, G. Chêne and the ILIADE Study Group. Effect of Intermittent Interleukin-2 Therapy on CD4+ T cell counts following antiretroviral cessation in patients with HIV (ANRS 118/NIH 04-I-0018 ILIADE Trial). AIDS 2012; 26(6):711-720.
    [9] C. Lewden, V. Bouteloup, S. De Wit, (…), G. Chêne and COHERE in EuroCoord. All-cause mortality in HIV-infected adults with CD4 ≥500 /mm3 compared to general population in a large European observational cohort collaboration. International Journal of Epidemiology 2012; 41(2):433-45.
    [10] Y. Lévy, C. Lacabaratz C, L Weiss, (…), R. Thiébaut, G. Chêne, M. Morre, J-F. Delfraissy. Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment. Journal of Clinical Investigation 2009; 119:997-1007.

    Head of division : Jean-Daniel LELIEVRE

    Jean Daniel LELIEVREJean-Daniel Lelièvre received his MD in Internal Medicine in 2002 (University Paris VII) and his PhD in immunology in 2002 (University Paris VII). He is professor in clinical immunology since 2010 and head the department of clinical immunology and infectious diseases of Henri Mondor’s hospital and the team 16 of INSERM U955.

    His basic research was focused on T cell apoptosis during HIV infectio n during his PhD (under the supervision of Pr JC Ameisen) and moved after on the biology of Treg during HIV infection and basic aspects of T-cell development (role of Notch and IL7) and their disturbance during HIV infection.

    Pr JD Lelièvre is currently the PI (or co-PI) of several clinical trials in the field of immune-based therapies of HIV or vaccinology (ANRS OPTIMAL role of treatment optimization with anti CCR5 in late diagnosis HIV + patients; ANRS LIGHT Therapeutic anti HIV vaccine, ANRS TREVE Kidney transplantation and raltegravir in HIV+ patients; ANRS VRI01, anti HIV prophylactic trial, EBOVAC2, anti Ebola vaccination).

    He is in the charge of the clinical core of the VRI and of the WP 8 (prophylactic vaccine) of EHVA (European HIV Vaccine Alliance) a European consortium which encompasses 39 partners, each with the expertise to promote a comprehensive approach to the development of an effective HIV vaccine. Pr Lelièvre JD is member of several committees of ANRS (CSS5, AC5, AC18) of the scientific and permanent committees of Sidaction, and of the program organizing committee of HIVR4P 2016.
    Jean-Daniel Lelièvre is one of the leaders of the Clinical Development division of the VRI


    Selected publications

    [1] Kared H, Lelièvre JD, Donkova-Petrini V, Aouba A, Melica G, Balbo M, Weiss L, Lévy Y. HIV-specific regulatory T cells are associated with higher CD4 cell counts in primary infection AIDS 2008, 22:2451-60.
    [2] Levy Y, Lacabaratz C, Weiss L, Viard JP, Goujard C, Lelièvre JD, Boué F, Molina JM, Rouzioux C, Avettand V, Croughs T, Beq S, Thiébaut R, Chêne G, Morre M, Delfraissy JF. Repeated doses of rhIL7 improve T-cell recoveryin chronically HIV-1 infected adults. Results of a phase I/II Multicentre Study Journal of Clinical Investigation 2009; 119(4):997-1007.
    [3] Nikolova M, Carriere M, Jenabian MA, Limou S, Younas M, Kök A, Huë S, Seddiki N, Hulin A, Delaneau O, Schuitemaker H, Herbeck JT, Mullins JI, Muhtarova M, Bensussan A, Zagury JF, Lelievre JD, Lévy Y. CD39/Adenosine pathway in HIV infection PLoS Pathogens 2011; 7 (7).
    [4] Lévy Y, Sereti I, Tambussi G, Routy JP, Lelièvre JD et al. Effects of rhIL-7 on T Cell Recovery and Thymic Output in HIV-infected Patients receiving antiretroviral therapy: results of a Phase I/IIa Randomized, Placebo Controlled, Multicenter Study. Clinical Infectious Diseases 2012; l;55(2):291-300.
    [5] Jenabian M-A, Seddiki N, Yatim A, Carriere M, Hulin A, Younas M, Ghadimi E, Kök A, Routy JP, Tremblay A, Sevigny J, Lelievre JD, Levy Y. Regulatory T Cells Negatively Affect IL-2 Production of Effector T Cells through CD39/Adenosine Pathway in HIV Infection. PLoS Pathogen 2013; 9(4): e1003319.
    [6] Younas M, Hue S, Lacabaratz C, Guguin A, Wiedemann A, Surenaud M, Beq S, Croughs T, Lelièvre JD°, and Lévy Y°. IL-7 modulates in vitro and in vivo human memory T regulatory cell functions through the CD39/ATP axis Journal of Immunology 2013,15; 191(6):3161-8. (° co-last authors)
    [7] Lahaye X, Satoh T, Cerboni S, Conrad C, Hurbain I, Marjou A, Lacabaratz C, Lelievre JD, Manel N. Cooperative cytosolic sensing of the HIV cDNA and capsid by dendritic cells elicits an adjuvant activity that stimulates innate and adaptive immunity without viral réplication Immunity, 2013; 39(6):1132-42.
    [8] L Richert, A Doussau, JD Lelièvre, V Arnold, V Rieux, A Bouakane, Y Lévy, G Chêne and R Thiébaut. Accelerating clinical development of HIV vaccine stratégies methodological challenges and considerations in constructing an optimised multi-arm phase I/II trial design Trials 2014; 15:68.
    [9] Carrière M, Lacabaratz C, Kök A, Benne C, Jenabian M, Casartelli N, Huë S, Hocqueloux L, Lelievre JD, and Levy Y. HIV “elite controllers” are characterized by a high frequency of memory CD8+CD73+ T-cells involved in the antigen-specific CD8+T-cell response accepté Journal of Infectious Diseases 2014; 209(9):1321-1330.
    [10] Menkova-Garnier I, Hocini H, Foucat E, Tisserand P, Bourdery L, Delaugerre C, Benne C, Lévy Y, Lelièvre JD. P2X7 Receptor Inhibition Improves CD34 T-Cell Differentiation in HIV-Infected Immunological Nonresponders on c-ART. PLoS Pathogens 2016; 12(4):e1005571.

    Valérie LAPIERRE

    To come

    Odile LAUNAY

    To come

    Frédéric LUCHT

    Frédéric LUCHT Frédéric Lucht received his MD in Internal Medicine in 1982 (University Claude Bernard LYON 1) and his DERBH in immunology in 1984 (University Claude Bernard Lyon 1).

    He is Professor in Infectious and Tropical Diseases since 1990 and head the department of Infectious and Tropical Diseases of CHU Saint Etienne. His basic research was focused on mucosal immunity during HIV infection and moved after also on Staphylococcus aureus nasal carriage and mucosal immunity.

    Pr F. Lucht is currently the PI (or co-PI) of several clinical trials in the field of immune-based therapies of HIV or vaccinology (ANRS LIGHT Therapeutic anti HIV vaccine, ANRS VRI01, THV01-11-01 with Theravectis) and Staphylococcus aureus (STRIVE with Pfizer in neurosurgical procedure) or other infectious agents (Clostridium difficile, VZV, EBOVAC2, anti-Ebola vaccination, Influenza,…).

    He is in charge of the CIC-INSERM1408-Vaccine clinical center integrated in a French network (REIVAC) and in I-REIVAC (European consortium of Clinical vaccine Centers labelled by F-CRIN).

    Frédéric Lucht is PI in the Clinical Development division of the VRI.


    Selected publications

    [1]
    Parienti JJ, Ragland K, Lucht F, de la Blanchardiere A, Dargere S, Yazdanpanah Y, Dutheil JJ, Perre P, Verdon R, and Bangsberg DR, for the ESPOIR and REACH study groups. Average Adherence to Boosted Protease Inhibitor Therapy, rather than the Pattern of Missed Doses, as a Predictor of HIV RNA Replication. Clinical Infectious Diseases 2010; 50:1192-7.
    [2] Berthelot P, Grattard F, Cazorla C, Passot JP, Fayard JP, Meley R, Bejuy J, Farizon F, Pozzetto B, Lucht F. Is nasal carriage of Staphylococcus aureus the main acquisition pathway for surgical-site infection in orthopaedic surgery? European Journal of Clinical Microbiology & Infectious Diseases 2010; 29:373-82.
    [3] Pozzetto B, Delezay O, Brunon-Gagneux A, Hamzeh-Cognasse H, Lucht F, Bourlet T. Current and futures microbicide approaches aimed at preventing HIV infection in women. Expert Review of Anti-infective Therapy. 2012; 10(2):167-83.
    [4] Verhoeven PO, Grattard F, Carricajo A, Lucht F, Cazorla C, Garraud O, Ph Berthelot, B. Pozzetto. Quantification by Real-Time PCR Assay of Staphylococcus aureus Load: a Useful Tool for Rapidly Identifying Persistent Nasal Carriers. Journal of Clinical Microbiology 2012; 18:2063-5.
    [5] Durier C, Desaint C, Lucht F, Girard PM, Lévy Y, May T, Michelet C, Bergmann JF, Katlama C, Grenier A, Roman F, Delfraissy JF, Aboulker JP, Launay O, for the ANRS 151 study group* and the REIVAC network. Long term immunogenicity of two doses of 2009 A/H1N1v vaccine formulated with and without AS03A-adjuvant in HIV-1-infected adults: ANRS 151 Randomized HIFLUVAC Trial. AIDS 2013; 27:87-93.
    [6] Damien P, Cognasse F, Lucht F, Suy F, Pozzetto B, Garraud O, and Hamzeh-Cognasse H. HAART alters inflammation linked to platelet cytokines in HIV-1 infected 1 patients. Journal of Infectious Diseases 2013; 208:868-70.
    [7] Botelho-Nevers E, Verhoeven P, Paul S, Grattard F, Pozzetto B, Berthelot P, Lucht F. Staphylococcal vaccine development: review of past failures and plea for mucosal decolonization assessment as a new surrogate marker. Expert Review Vaccines 2013; 12:1249-59.
    [8] Suy F, Botelho-Nevers E, Gagneux-Brunon A, Frésard A, Paul S, Lambert C, Pozzetto B, Lucht F. Immunologic non-responders and T regulatory cells in HIV-1 infection. AIDS 2013; 27:2968-71.
    [9] Launay O, Paul S, Servettaz A, Roguet G, Rozenberg F, Lucht F, Lambert C, Presles E, Goulvestre C, Méritet JF, Galtier F, Dubray C, Lebon P, Weill B, Batteux F. Control of humoral immunity and auto-immunity by the CXCR4/CXCL12 axis in lupus patients following influenza vaccine. Vaccine 2013; 31:3492-501.
    [10] Botelho-Nevers E, Berthelot P, Verhoeven PO, Grattard F, Cazorla C, Farizon F, Pozzetto B, Lucht F. Are the risk factors associated with Staphylococcus aureus nasal carriage in patients the same than in healthy volunteers? Data from a cohort of patients scheduled for orthopedic material implantation. American Journal of Infection Control 2014; 42:1121-3.

    Caroline OLLIVIER-YANIV

    Caroline OLLIVIER YANIVCaroline Ollivier-Yaniv, born in 1970, PhD in Political Sciences (University Paris 1 – Panthéon Sorbonne), is a full professor in Sciences of Information and Communication at the University Paris-Est Créteil since 2009. She is the co-director of the Ceditec (Center for the Study of Discourses, Images, Written Texts and Communication, E.A. 3119) and she was the head of the Master “Political and Public Communication in France and in Europe” until 2015. In spring 2012 she was Visiting Fellow at the Institute of Advanced Studies of the University of Bologna.

    Caroline Ollivier-Yaniv simultaneously held various positions in the Executive Board of the University Paris-Est Créteil: vice-president for communication (2001-2007), vice-president for Human and Social Sciences (2012-2016). Since 2012 she is elected to the Administrative Board of the University.

    She conducts research on the social actors, their practices, their discourses and their careers, involved in political and institutional communication – and propaganda - of the States, in France and in some other European countries. She is also interested in analyzing the political issues of this phenomenon: the legitimacy of the political work, the building of social order and norms. In 2011, she became a member of the Institut Universitaire de France for a project dealing with the professional actors involved in public health communication.

    For a few years her research has been focused on public health communication (cancer, smoking…) in general and on the public debates and media controversies about vaccination. Within the Vaccine Research Institute she has developed with Mathilde Courderc a research about the participation and the commitment in an HIV preventive vaccine trial.


    Selected publications

    [1] C. Ollivier-Yaniv, M. Couderc, C. Fagard, L. Hardel, Véronique Rieux, Amel Bouakane, O. Launay, J.-D. Lelièvre, “How to recruit healthy volunteers? Becoming participant in an HIV preventive vaccine Trial in France in 2014.” HIVR4P 2016.
    [2] “S’engager dans un essai vaccinal préventif anti-VIH. Perceptions du recrutement et motifs d’engagement des volontaires de l’essai ANRS-VRI01. Approche socio-anthropologique”, Vaccine Research Institute, avril 2016, en collaboration avec Mathilde Couderc.
    [3] “La communication publique sanitaire à l’épreuve des controverses“, Hermès, dossier “Controverses et communication“, Paris, Presses du CNRS, n°73, décembre 2015, pp. 69-80.

    Isabelle POIZOT-MARTIN

    Dr Isabelle Poizot-Martin is head of the Immuno Hematology Service, a multidisciplinary outpatient unit at Sainte Marguerite in Marseille. This unit monitors the follow up of almost 1,000 patients infected with HIV, of which 40% are co-infected with hepatitis C.

    Specialist in onco-hematology and dermato-venereology, Dr. Isabelle Poizot -Martin was involved from the beginning of the HIV epidemic. Apart from a strong clinical research activity in the field of HIV infection and its comorbidities and hepatitis viruses B and C, she is also engaged in anti-HIV preventive vaccine research since 2000 and has participated in three recruitment campaigns of healthy volunteer and realization of three preventive vaccine trials sponsored by the ANRS (ANRS VAC16, VAC18 and VAC20). She is co-investigator of the VRI01 trial.

    Involved in various “coordinated actions” of the ANRS, Dr Isabelle Poizot Martin is coordinating since May 2014 with Prof. Jean Philippe Spano (oncologist) and Professor F Boue (hematologist) a national multidisciplinary meeting (RCP: réunion de concertation pluridisciplinaire) called "ONCOVIH" in the CANCERVIH Network supported by the INCA (Institut National du Cancer) and the DGOS (Direction régionale de l’offre de soins).

    She is also a member of the group of experts responsible for drafting national guidelines for the medical care of people living with HIV (Morlat Report), as well as national guidelines for the treatment of viral hepatitis (Dhumeaux Report).

    Isabelle Poizot-Martin is PI in the Clinical Development division of the VRI.


    Selected publications

    [1] Launay O, Surenaud M, Desaint C, Ben Hamouda N, Pialoux G, Bonnet B, Poizot-Martin I, Gonzales G, Cuzin L, Bourgault-Villada I, Lévy Y, Choppin J, Durier C. Long-term CD4(+) and CD8(+) T-cell responses induced in HIV-uninfected volunteers following intradermal or intramuscular administration of an HIV-lipopeptide vaccine (ANRS VAC16). Vaccine 2013; 31(40):4406-15.
    [2] Salmon-Céron D, Durier C, Desaint C, Cuzin L, Surenaud M, Hamouda NB, Lelièvre JD, Bonnet B, Pialoux G, Poizot-Martin I, Aboulker JP, Lévy Y, Launay O; ANRS VAC18 trial group. Immunogenicity and safety of an HIV-1 lipopeptide vaccine in healthy adults: a phase 2 placebo-controlled ANRS trial. AIDS 2010; 24(14):2211-23.
    [3] Launay O, Durier C, Desaint C, Silbermann B, Jackson A, Pialoux G, Bonnet B, Poizot-Martin I, Gonzalez-Canali G, Cuzin L, Figuereido S, Surenaud M, Ben Hamouda N, Gahery H, Choppin J, Salmon D, Guérin C, Bourgault Villada I, Guillet JG; ANRS VAC16 Study Group. Cellular immune responses induced with dose-sparing intradermal administration of HIV vaccine to HIV-uninfected volunteers in the ANRS VAC16 trial. PLoS One 2007; 2(8):e725.

    Linda WITTKOP

    To come

  • Division BIOSTATISTICS & BIOINFORMATICS

    Head of division : Rodolphe THIEBAUT

    Rodolphe THIEBAUTRodolphe Thiébaut has been trained as a medical doctor specialized in Public Health. He did a PhD in Biostatistics at Bordeaux University in France. He started his research carrier at the Inserm as a researcher in 2002 and research director between 2010 and 2013.

    He has been research fellow in the Immunology division of the Institute of Child Health in 2007. He is now deputy head of the INSERM U1219 research centre and professor in Public Health / Biostatistics at the University of Bordeaux. He is co-coordinator of the Epidemiology specialty for the second year of the Master at ISPED (Institut de Santé Publique d'Epidémiologie et de Dévelopement).

    He is leading a research group (SISTM-Statistics in Systems Biology and Translational Medicine) devoted to the design and analysis of clinical trials mainly in HIV immunology through the French Vaccine Research Institute. This group, which is embedded in the Inserm U1219 research centre, has been recognized as an INRIA project team since January 2015. Its translational research starts with immunological questions and end with the development of statistical methods for the collection and analysis of high-dimensional datasets generated in this domain.

    He is leading the “Biostatistics/Bioinformatics” division of the Vaccine Research Institute and is in charge of the clinical trial unit of the Bordeaux University Hospital. He is also project coordinator of EBOVAC2 project (IMI2 Ebola vaccine project). Rodolphe Thiébaut is the author/co-author of more than 160 publications in peer-reviewed journals including New England Journal, Lancet, AIDS, Journal of Immunology, Biometrics, Statistics in Medicine, Plos Computational Biology.

    Rodolphe Thiébaut is the leader of the Biostatistics and Bioinformatics division of the VRI.


    Selected publicactions

    [1] Zurawski G, Zurawski S, Flamar AL, Richert L, Wagner R, Tomaras GD, Montefiori DC, Roederer M, Ferrari G, Lacabaratz C, Bonnabau H, Klucar P, Wang Z, Foulds KE, Kao SF, Yates NL, LaBranche C, Jacobs BL, Kibler K, Asbach B, Kliche A, Salazar A, Reed S, Self S, Gottardo R, Galmin L, Weiss D, Cristillo A, Thiebaut R, Pantaleo G, Levy Y. Targeting HIV-1 Env gp140 to LOX-1 Elicits Immune Responses in Rhesus Macaques. PloS One. 2016; 11(4):e0153484.
    [2] Thiébaut R, Jarne A, Routy JP, Sereti I, Fischl M, Ive P, Speck RF, D'Offizi G, Casari S, Commenges D, Foulkes S, Natarajan V, Croughs T, Delfraissy JF, Tambussi G, Levy Y, Lederman MM. Repeated Cycles of Recombinant Human Interleukin-7 in HIV-Infected Patients with low CD4 T cell Reconstitution on Antiretroviral Therapy: Results of two Phase II Multicentre Studies. Clinical Infectious Diseases 2016; 62(9):1178-85.
    [3] Liquet B, de Micheaux PL, Hejblum BP, Thiébaut R. Group and sparse group partial least square approaches applied in genomics context. Bioinformatics 2016; 32(1):35-42.
    [4] Brezar V, N. Ruffin, L. Richert, M. Surenaud, C. Lacabaratz, K. Palucka, R. Thiébaut, J. Banchereau, Y. Levy and N. Seddiki. Decreased HIV-specific T-regulatory responses are associated with effective DC-vaccine induced immunity. PLoS Pathogens 2015; 11(3):e1004752.
    [5] Richert L, Lhomme E, Fagard C, Lévy Y, Chêne G, Thiébaut R. Recent developments in clinical trial designs for HIV vaccine research. Hum Vaccines & Immunotherapeutics. 2015; 11(4):1022-9.
    [6] Lévy Y, Thiébaut R, Montes M, Lacabaratz C, Sloan L, King B, Pérusat S, Harrod C, Cobb A, Roberts LK, Surenaud M, Boucherie C, Zurawski S, Delaugerre C, Richert L, Chêne G, Banchereau J, Palucka K. Dendritic cell-based therapeutic vaccine elicits polyfunctional HIV-specific T-cell immunity associated with control of viral load. European Journal of Immunology 2014; 44(9):2802-10.
    [7] Richert L, Doussau A, Lelièvre JD, Arnold V, Rieux V, Bouakane A, Lévy Y, Chêne G, Thiébaut R. Accelerating clinical development of HIV vaccine strategies: methodological challenges and considerations in constructing an optimised multi-arm phase I/II trial design. Trials 2014;15:68.
    [8] Thiébaut R, Drylewicz J, Prague M, Lacabaratz C, Beq S, Jarne A, Croughs T, Sekaly RP, Lederman MM, Sereti I, Commenges D, Lévy Y. Quantifying and Predicting the Effect of Exogenous Interleukin-7 on CD4+T Cells in HIV-1 Infection. PLoS Computational Biology 2014 ;10:e1003630.
    [9] Richert L, Hue S, Hocini H, Raimbault M, Lacabaratz C, Surenaud M, Wiedemann A, Tisserand P, Durier C, Salmon D, Lelièvre JD, Chêne G, Thiébaut R, Lévy Y; for the ANRS Vaccine Network Vaccine Research Institute. Cytokine and gene transcription profiles of immune responses elicited by HIV lipopeptide vaccine in HIV-negative volunteers. AIDS 2013;27:1421-1431.
    [10] Liquet B, Le Cao KA, Hocini H, Thiébaut R. A novel approach for biomarker selection and the integration of repeated measures experiments from two assays. BMC Bioinformatics 2012;13:325.

  • Division IMMUNO-MONITORING

    Head of division : Christine LACABARATZ

    Christine LACABARATZChristine Lacabaratz is a PhD. Her research interests are cellular immunity in HIV infection. She has contributed to describe the evolution of CD8 responses in a large cohort of acutely HIV-infected patients and in HIV controllers. She heads the immuno-monitoring platform of the VRI (Mondor Immuno-monitoring Center, MIC) which has developed SOP for the different assays according to international standards (T cell phenotype, Flow cytometry and Intracellular Staining assays, multiplex cytokine production, in vitro functional assays), within its participation to different European consortium.

    The MIC is currently involved in evaluation of HIV-specific immune responses of HIV-infected or healthy subjects (Light and VRI01 trials) and Ebola-specific immune responses of vaccinated individuals (Co-leader of EBOVAC2 European trial WP3 on immuno-monitoring and PREVAC African trial) and individuals surviving the 2014 Ebola outbreak (INSERM PostEbogui Cohort).

    Christine Lacabaratz is the leader of the Immuno-monitoring division of the VRI.


    Selected publications

    [1] Zurawski G, Zurawski S, Flamar A-L, Richert L, Wagner R, Tomaras G, Montefiori D, Roederer M, Ferrari G, Lacabaratz C, Bonnabau H, Klucar P, Wang Z, Foulds K, Kao S-F, Yates N, LaBranche C, Jacobs B, Kibler K, Asbach B, Kliche A, Salazar A, Reed S, Shelf S, Gottardo R, Galmin L, Weiss D, Cristillo A, Thiebaut R, Pantaleo G, Lévy Y. Targeting HIV-1 Env gp140 to LOX-1 elicits immune responses in Rhesus macaques. Plos One 2016, 11(4):e0153484
    [2] Brezar V, Ruffin N, Richert L, Surenaud M, Lacabaratz C, Palucka K, Thiébaut R, Banchereau J, Levy Y and Seddiki N. Decreased HIV-specific T-regulatory responses are associated with effective DC-vaccine induced immunity. Plos Pathogens 2015, Mar 27;11(3):e1004752.
    [3] Colson P, Ravaux I, Tamalet C, Glazunova O, Baptiste E, Chabriere E, Wiedemann A, Lacabaratz C, Chefrour M, Picard C, Stein A, Levy Y, Raoult D. HIV infection en route to endogenization: two cases. Clinical Microbiology and Infection 2014, 20(12):1280-1288.
    [4] Perreau M, Vigano S, Bellanger F, Pellaton C, Buss G, Comte D, Roger T, Lacabaratz C, Bart PA, Levy Y, Pantaleo G. Exhaustion of bacteria-specific CD4 T cells and microbial translocation in common variable immunodeficiency disorders. Journal of Experimental Medicine 2014, 211(10):2033-2045.
    [5] Lévy Y, Thiébaut R, Montes M, Lacabaratz C, Sloan L , King B, Pérusat S, Harrod C, Cobb A, Roberts LK, Surenaud M, Boucherie C, Zurawski S, Delaugerre C, Richert L, Chêne G, Banchereau J, Palucka K on behalf of the Vaccine Research Institute. Dendritic Cell-based therapeutic vaccine elicits polyfunctional HIV-specific T cell immunity associated with control of viral load. European Journal of Immunology 2014, 44: 2802–2810.
    [6] Thiébaut R, Drylewicz J, Prague M, Lacabaratz C, Beq S, Jame A, Croughs T, Sekaly RP, Lederman MM, Sereti I, Commenges D, Levy Y. Quantifying and Predicting the Effect of exogenous Interleukin‐7 on CD4+T cells In HIV‐1 Infection. PLoS Computational Biology 2014, 10(5):e1003630.
    [7] Carrière M, Lacabaratz C, Kök A, Benne C, Jenabian MA, Casartelli N, Hüe S, Hocqueloux L, Lelièvre JD and Lévy Y. HIV “elite controllers” are characterized by a high frequency of memory CD8+CD73+ T cells involved in the antigen-specific CD8+ T-cell response. Journal of Infectious Diseases 2014, 209(9):1321-1330.
    [8] Lahaye X, Satoh T, Gentilli M, Cerboni S, Conrad C, Hurbain I, El Marjou A, Lacabaratz C, Lelièvre JD, Manel N. The capsid of HIV-1 and HIV-2 determine immune detection of the viral cDNA by the innate sensor cGAS in Dendritic Cells. Immunity 2013, 39(6):1132-1142.
    [9] Younas M, Hue S, Lacabaratz C, Guguin A, Wiedemann A, Surenaud M, Becq S, Croughs T, Lelièvre JD and Lévy Y. IL-7 modulates in vitro and in vivo human memory T regulatory cell functions through the CD39/ATP axis. Journal of Immunology 2013, 191(6):3161-3168.
    [10] Richert L, Hue S, Hocini H, Raimbault M, Lacabaratz C, Surenaud M, Wiedemann A, Tisserand P, Durier C, Salmon D, Lelievre J-D, Chêne G, Thiebaut R, Lévy Y for the ANRS Vaccine Network / Vaccine Research Institute. Cytokine and gene transcription profiles of immune responses elicited by HIV lipopeptide vaccine in HIV-negative volunteers. AIDS 2013, 27(9):1421-1431.

    Hakim HOCINI

    Hakim HOCINIHakim Hocini received his PhD in microbiology from the university Paris-Sud (France) and his HDR (accreditation to supervise research) in immunology from the university Paris Descartes, following his work in the laboratory of Pr Michel Kazatchkine on the characterization of immune and viral mechanisms involved in mucosal transmission of HIV.

    Dr Hakim Hocini was responsible of mucosal immunology laboratory at les Cordeliers institute at Paris before joining the Vaccine Research Institute in 2010 to lead the genomic laboratory.

    Hakim Hocini is PI in the Immuno-monitoring division of the VRI.


    Selected publicactions

    [1] Menkova-Garnier I, Hocini H, Foucat E, Tisserand P, Bourdery L, Delaugerre C, Benne C, Levy Y, Lelievre JD. 2016. P2X7 Receptor Inhibition Improves CD34 T-Cell Differentiation in HIV-Infected Immunological Nonresponders on c-ART. PLoS Pathogens 12:e1005571.
    [2] Kok A, Hocqueloux L, Hocini H, Carriere M, Lefrou L, Guguin A, Tisserand P, Bonnabau H, Avettand-Fenoel V, Prazuck T, Katsahian S, Gaulard P, Thiebaut R, Levy Y, Hue S. 2015. Early initiation of combined antiretroviral therapy preserves immune function in the gut of HIV-infected patients. Mucosal Immunol 8:127-140.
    [3] Richert L, Hue S, Hocini H, Raimbault M, Lacabaratz C, Surenaud M, Wiedemann A, Tisserand P, Durier C, Salmon D, Lelievre JD, Chene G, Thiebaut R, Levy Y. 2013. Cytokine and gene transcription profiles of immune responses elicited by HIV lipopeptide vaccine in HIV-negative volunteers. AIDS 27:1421-1431.
    [4] Liquet B, Le Cao KA, Hocini H, Thiebaut R. 2012. A novel approach for biomarker selection and the integration of repeated measures experiments from two assays. BMC Bioinformatics 13:325.
    [5] Nasreddine N, Borde C, Gozlan J, Belec L, Marechal V, Hocini H. 2011. Advanced glycation end products inhibit both infection and transmission in trans of HIV-1 from monocyte-derived dendritic cells to autologous T cells. Journal of Immunology 186:5687-5695.
    [6] Requena M, Bouhlal H, Nasreddine N, Saidi H, Gody JC, Aubry S, Gresenguet G, Kazatchkine MD, Sekaly RP, Belec L, Hocini H. 2008. Inhibition of HIV-1 transmission in trans from dendritic cells to CD4+ T lymphocytes by natural antibodies to the CRD domain of DC-SIGN purified from breast milk and intravenous immunoglobulins. Immunology 123:508-518.
    [7] Chomont N, Hocini H, Gresenguet G, Brochier C, Bouhlal H, Andreoletti L, Becquart P, Charpentier C, de Dieu Longo J, Si-Mohamed A, Kazatchkine MD, Belec L. 2007. Early archives of genetically-restricted proviral DNA in the female genital tract after heterosexual transmission of HIV-1. AIDS 21:153-162.
    [8] Becquart P, Chomont N, Roques P, Ayouba A, Kazatchkine MD, Belec L, Hocini H. 2002. Compartmentalization of HIV-1 between breast milk and blood of HIV-infected mothers. Virology 300:109-117.
    [9] Hocini H, Becquart P, Bouhlal H, Chomont N, Ancuta P, Kazatchkine MD, Belec L. 2001. Active and selective transcytosis of cell-free human immunodeficiency virus through a tight polarized monolayer of human endometrial cells. Journal of Virology 75:5370-5374.
    [10] Bomsel M, Heyman M, Hocini H, Lagaye S, Belec L, Dupont C, Desgranges C. 1998. Intracellular neutralization of HIV transcytosis across tight epithelial barriers by anti-HIV envelope protein dIgA or IgM. Immunity 9:277-287.

The LabEx VRI is supported by the “Investissements d’Avenir” program managed by the ANR under reference ANR-10-LABX-77